



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Laparoscopic versus open gastrectomy for gastric cancer (Review)

Best LMJ, Mughal M, Gurusamy KS

Best LMJ, Mughal M, Gurusamy KS.

Laparoscopic versus open gastrectomy for gastric cancer.

*Cochrane Database of Systematic Reviews* 2016, Issue 3. Art. No.: CD011389.

DOI: 10.1002/14651858.CD011389.pub2.

[www.cochranelibrary.com](http://www.cochranelibrary.com)

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . .	4
BACKGROUND . . . . .	6
OBJECTIVES . . . . .	7
METHODS . . . . .	7
RESULTS . . . . .	11
Figure 1. . . . .	12
Figure 2. . . . .	14
Figure 3. . . . .	15
ADDITIONAL SUMMARY OF FINDINGS . . . . .	19
DISCUSSION . . . . .	22
AUTHORS' CONCLUSIONS . . . . .	23
ACKNOWLEDGEMENTS . . . . .	23
REFERENCES . . . . .	23
CHARACTERISTICS OF STUDIES . . . . .	27
DATA AND ANALYSES . . . . .	49
Analysis 1.1. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 1 Short-term mortality. . . . .	50
Analysis 1.2. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 2 Long-term mortality (maximal follow-up). . . . .	51
Analysis 1.3. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 3 Proportion with a serious adverse event (< 3 months). . . . .	52
Analysis 1.4. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 4 Short-term recurrence. . . . .	53
Analysis 1.5. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 5 Long-term recurrence (maximal follow-up). . . . .	53
Analysis 1.6. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 6 Proportion with an adverse event (< 3 months). . . . .	54
Analysis 1.7. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 7 Proportion requiring blood transfusion during or within a week of surgery. . . . .	55
Analysis 1.8. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 8 Quantity of perioperative blood transfused. . . . .	55
Analysis 1.9. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 9 Length of hospital stay. . . . .	56
Analysis 1.10. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 10 Proportion with positive resection margins at histopathological examination. . . . .	57
Analysis 1.11. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 11 Number of lymph nodes harvested. . . . .	57
Analysis 2.1. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 1 Short-term mortality (stratified by early versus advanced cancer). . . . .	58
Analysis 2.2. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 2 Long-term mortality (maximal follow-up) (stratified by early versus advanced cancer). . . . .	59
Analysis 2.3. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 3 Proportion with a serious adverse event (< 3 months) (stratified by early versus advanced cancer). . . . .	60
Analysis 2.4. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 4 Short-term mortality (stratified by type of gastrectomy). . . . .	61
Analysis 2.5. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 5 Long-term mortality (maximal follow-up) (stratified by type of gastrectomy). . . . .	62
Analysis 2.6. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 6 Proportion with a serious adverse event (< 3 months) (stratified by type of gastrectomy). . . . .	63
APPENDICES . . . . .	63
WHAT'S NEW . . . . .	65
CONTRIBUTIONS OF AUTHORS . . . . .	66

DECLARATIONS OF INTEREST . . . . .	66
SOURCES OF SUPPORT . . . . .	66
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . .	67

[Intervention Review]

# Laparoscopic versus open gastrectomy for gastric cancer

Lawrence MJ Best<sup>1</sup>, Muntzer Mughal<sup>2</sup>, Kurinchi Selvan Gurusamy<sup>1</sup>

<sup>1</sup>Department of Surgery, Royal Free Campus, UCL Medical School, London, UK. <sup>2</sup>University College Hospital, London, UK

Contact address: Kurinchi Selvan Gurusamy, Department of Surgery, Royal Free Campus, UCL Medical School, Rowland Hill Street, London, NW32PF, UK. [k.gurusamy@ucl.ac.uk](mailto:k.gurusamy@ucl.ac.uk).

**Editorial group:** Cochrane Upper GI and Pancreatic Diseases Group.

**Publication status and date:** Edited (no change to conclusions), published in Issue 3, 2016.

**Review content assessed as up-to-date:** 5 September 2015.

**Citation:** Best LMJ, Mughal M, Gurusamy KS. Laparoscopic versus open gastrectomy for gastric cancer. *Cochrane Database of Systematic Reviews* 2016, Issue 3. Art. No.: CD011389. DOI: 10.1002/14651858.CD011389.pub2.

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Gastric cancer is the third most common cause of cancer-related mortality in the world. Currently there are two surgical options for potentially curable patients (i.e. people with non-metastatic gastric cancer), laparoscopic and open gastrectomy. However, it is not clear whether one of these options is superior.

### Objectives

To assess the benefits and harms of laparoscopic gastrectomy or laparoscopy-assisted gastrectomy versus open gastrectomy for people with gastric cancer. In particular, we planned to investigate the effects by patient groups, such as cancer stage, anaesthetic risk, and body mass index (BMI), and by intervention methods, such as method of anastomosis, type of gastrectomy and laparoscopic or laparoscopically-assisted gastrectomy.

### Search methods

We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Science Citation Index, ClinicalTrials.gov and the WHO ICTRP (World Health Organization International Clinical Trials Registry Platform) until September 2015. We also screened reference lists from included trials.

### Selection criteria

Two review authors independently selected references for further assessment by going through all titles and abstracts. Further selection was based on review of full text articles for selected references.

### Data collection and analysis

Two review authors independently extracted study data. We calculated the risk ratio (RR) with 95% confidence interval (CI) for binary outcomes, the mean difference (MD) or the standardised mean difference (SMD) with 95% CI for continuous outcomes and the hazard ratio (HR) for time-to-event outcomes. We performed meta-analyses where it was meaningful.

### Main results

In total, 2794 participants were randomised in 13 trials included in this review. All the trials were at unclear or high risk of bias. One trial (which included 53 participants) did not contribute any data to this review. A total of 213 participants were excluded in the remaining trials after randomisation, leaving a total of 2528 randomised participants for analysis, with 1288 undergoing laparoscopic gastrectomy and 1240 undergoing open gastrectomy. All the participants were suitable for major surgery.

---

**Laparoscopic versus open gastrectomy for gastric cancer (Review)**

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

There was no difference in the proportion of participants who died within thirty days of treatment between laparoscopic gastrectomy (7/1188: adjusted proportion = 0.6% (based on meta-analysis)) and open gastrectomy (4/1447: 0.3%) (RR 1.60, 95% CI 0.50 to 5.10; risk difference 0.00, 95% CI -0.01 to 0.01; participants = 2335; studies = 11;  $I^2 = 0\%$ ; low quality evidence). There were no events in either group for short-term recurrence (participants = 103; studies = 3), proportion requiring blood transfusion (participants = 66; studies = 2), and proportion with positive margins at histopathology (participants = 28; studies = 1). None of the trials reported health-related quality of life, time to return to normal activity or time to return to work. The differences in long-term mortality (HR 0.94, 95% CI 0.70 to 1.25; participants = 195; studies = 3;  $I^2 = 0\%$ ; very low quality evidence), serious adverse events within three months (laparoscopic gastrectomy (7/216: adjusted proportion = 3.6%) versus open gastrectomy (13/216: 6%) (RR 0.60, 95% CI 0.27 to 1.34; participants = 432; studies = 8;  $I^2 = 0\%$ ; very low quality evidence), long-term recurrence (HR 0.95, 95% CI 0.70 to 1.30; participants = 162; studies = 4; very low quality evidence), adverse events within three months (laparoscopic gastrectomy (204/268: adjusted proportion = 16.1%) versus open gastrectomy (253/1222: 20.7%) (RR 0.78, 95% CI 0.60 to 1.01; participants = 2490; studies = 11;  $I^2 = 38\%$ ; very low quality evidence), quantity of perioperative blood transfused (SMD 0.05, 95% CI -0.27 to 0.38; participants = 143; studies = 2;  $I^2 = 0\%$ ; very low quality evidence), length of hospital stay (MD -1.82 days, 95% CI -3.72 to 0.07; participants = 319; studies = 6;  $I^2 = 83\%$ ; very low quality evidence), and number of lymph nodes harvested (MD -0.63, 95% CI -1.51 to 0.25; participants = 472; studies = 9;  $I^2 = 40\%$ ; very low quality evidence) were imprecise. There was no alteration in the interpretation of the results in any of the subgroups.

### Authors' conclusions

Based on low quality evidence, there is no difference in short-term mortality between laparoscopic and open gastrectomy. Based on very low quality evidence, there is no evidence for any differences in short-term or long-term outcomes between laparoscopic and open gastrectomy. However, the data are sparse, and the confidence intervals were wide, suggesting that significant benefits or harms of laparoscopic gastrectomy cannot be ruled out. Several trials are currently being conducted and interim results of these trials have been included in this review. These trials need to perform intention-to-treat analysis to ensure that the results are reliable and report the results according to the CONSORT Statement.

## PLAIN LANGUAGE SUMMARY

### Laparoscopic (key hole) operation versus open operation for treatment of people with stomach cancer

#### Review question

Is laparoscopic treatment (key hole surgery) equivalent to open surgical treatment for treatment of people with gastric (stomach) cancer?

#### Background

Stomach cancer is the third most frequent cause of cancer-related death in the world. If cancer has not spread to other areas of the body, and if the person can withstand a major operation, depending upon the part of the stomach involved, removal of part of the stomach, or the entire stomach (gastrectomy), is the only treatment that offers long-term cure of cancer. Gastrectomy can be performed by laparoscopic (key hole) operation, or by open operation, which involves a large cut. While the cut is smaller with key hole surgery, it is not clear whether key hole surgery is as safe as open surgery, and whether it offers any advantages in terms of quicker recovery of people undergoing gastrectomy. We sought to resolve this issue by searching the medical literature for studies reported until September 2015 that compared laparoscopic and open gastrectomy in people with stomach cancer.

#### Study characteristics

We identified 13 eligible studies (2794 participants) for this review. One trial did not report any information that we sought. Information on 213 participants was not reported because of various reasons, the common reason being that they did not receive the planned treatment. A total of 2528 participants received either laparoscopic gastrectomy (1288 participants) or open gastrectomy (1240 participants). The decision on whether a participant received laparoscopic or open gastrectomy was made using methods similar to the toss of a coin. This process ensures that the participants in the two groups are similar. All the participants were suitable for major surgery.

#### Key results

There was no difference between laparoscopic and open gastrectomy in short-term deaths (laparoscopic gastrectomy: 6 deaths in 1000 operations versus open gastrectomy: 3 deaths in 1000 operations). There is a certain amount of uncertainty when predicting the number

of deaths or outcomes based on information in the trials. Because of this uncertainty, we were able to conclude that there was no difference in short-term deaths between the groups, although the deaths in laparoscopic gastrectomy was twice that in open gastrectomy. None of the trials reported health-related quality of life, time to return to normal activity or time to return to work. The differences in long-term deaths, serious complications within three months (laparoscopic gastrectomy: 36 complications per 1000 operations versus open gastrectomy: 60 complications per 1000 operations), all complications within three months (laparoscopic gastrectomy: 161 complications per 1000 operations versus open gastrectomy: 253 complications in 1000 operations, short-term and long-term recurrence of cancer, number of people who required blood transfusion, amount of blood transfused during or within one week of surgery, and length of hospital stay were imprecise. As a result, significant benefits or harms of laparoscopic gastrectomy compared to open gastrectomy cannot be ruled out. Further well designed trials are necessary to compare the benefits and harms of laparoscopic and open gastrectomy.

### **Quality of the evidence**

The quality of evidence was very low for all outcomes, apart from short-term mortality, which was low. As a result, there is a lot of uncertainty regarding the results.

## SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

Laparoscopic gastrectomy compared to open gastrectomy for gastric cancer (primary outcomes)					
<b>Patient or population:</b> patients with gastric cancer <b>Settings:</b> secondary or tertiary setting <b>Intervention:</b> laparoscopic gastrectomy <b>Comparison:</b> open gastrectomy					
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk			
	Open gastrectomy	Laparoscopic gastrectomy			
Short-term mortality	3 per 1000	6 per 1000 (2 to 18)	RR 1.60 (0.50 to 5.10)	2335 (11 studies)	⊕⊕○○ low <sup>1</sup>
Long-term mortality (maximal follow-up)	448 per 1000	428 per 1000 (340 to 524)	HR 0.94 (0.70 to 1.25)	195 (3 studies)	⊕○○○ very low <sup>1,2</sup>
Proportion with a serious adverse event (<3 months)	60 per 1000	36 per 1000 (16 to 81)	RR 0.60 (0.27 to 1.34)	432 (8 studies)	⊕○○○ very low <sup>1,2</sup>
Health-related quality of life during short-term (four weeks to three months) or medium-term (more than three months to one year) was not reported					
*The basis for the <b>assumed risk</b> was the mean control group proportion. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> risk ratio.					
GRADE Working Group grades of evidence <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect. <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. <b>Very low quality:</b> We are very uncertain about the estimate.					

<sup>1</sup> There was unclear or high risk bias within the trials (downgraded by two levels).

<sup>2</sup> The confidence intervals were wide (overlaps no effect and clinically significantly effect) and the sample size was small (downgraded by two levels).



## BACKGROUND

### Description of the condition

Adenocarcinoma of the stomach (or stomach cancer) is the fifth most common cancer and the third most common cause of cancer-related mortality in the world (IARC 2014). In 2012, there were about 950,000 newly diagnosed cases of gastric cancer and 725,000 deaths due to gastric cancer globally (IARC 2014). There is global variation in the incidence of gastric cancers with an age-standardised annual incidence rate of 30 to 42 per 100,000 population in East Asian countries such as Japan, Mongolia, and Korea compared with an age-standardised annual incidence rate of 1 to 5 per 100,000 population in Africa, Australia, the USA, and the UK (IARC 2014). The trend in mortality is different. For example, the age-standardised annual mortality rate in Mongolia is 25 per 100,000 population compared with 13 per 100,000 population in Korea and Japan despite a higher age-standardised annual incidence in Korea than Mongolia (IARC 2014).

There is a decreasing trend in the overall incidence of gastric cancers, possibly due to lifestyle changes, such as decreased consumption of salted and preserved foods, increased consumption of fruits and vegetables, decreased smoking and reduction of *Helicobacter pylori* (*H. pylori*) (Cancer Research UK 2014; Jemal 2010).

The treatment of gastric cancer depends upon the stage of cancer. One of the common systems for staging cancer currently is the American Joint Committee on Cancer (AJCC) gastric cancer staging system - AJCC 7th edition (AJCC 2010; Washington 2010). This system is based on the involvement of the different layers of the stomach by the tumour (T), nodal involvement (N), and the presence of metastases (M) (TNM classification). Early gastric cancer is cancer that is confined to the submucosa (T1) with or without nodal involvement, although this definition of early gastric cancer has been challenged since nodal status is an important prognostic factor in survival (Inoue 1991; Kim 1995). If the cancer has penetrated beyond the submucosa, it is called advanced gastric cancer. Metastatic gastric cancer corresponds to Stage IV of the AJCC gastric cancer staging system. The survival after diagnosis of gastric cancer depends upon the stage with five-year survival ranging from 70% in Stage Ia cancer to 5% in Stage IV cancer (AJCC 2010; Washington 2010). The treatment of gastric cancer depends upon the stage of the disease. Potentially curative treatment is possible for stages I to III (Japanese Gastric Cancer Association 2011; Waddell 2013). Apart from T<sub>1a</sub>N<sub>0</sub>M<sub>0</sub> stage, where endoscopic treatment may be performed, and stage IV, where palliative treatment is recommended, the remaining stages are treated by resection of the stomach (gastrectomy) (Bennett 2009; Japanese Gastric Cancer Association 2011; Waddell 2013).

### Description of the intervention

In open gastrectomy, the surgical access to the abdominal cavity (and hence the stomach) is by upper midline incision, a bilateral subcostal incision (roof-top or Chevron incision), or a transverse abdominal incision (Inaba 2004; Stuart 1997). In laparoscopy-assisted gastrectomy, the surgical access to the abdominal cavity (and hence the stomach) is by a small abdominal incision (about 5 cm) and additional five or six small ports (holes) of about 0.5 cm to 1 cm each through which laparoscopic instruments can be inserted after the abdomen is distended using carbon dioxide pneumoperitoneum. Part of the surgery, usually the anastomosis restoring the continuity of the gastrointestinal tract, is performed outside the body (extracorporeal) (Lee 2013). The resected stomach is removed through the small abdominal incision. In totally laparoscopic gastrectomy, the surgical access to the abdominal cavity (and hence the stomach) is only by five or six small ports of about 0.5 to 1 cm each through which laparoscopic instruments can be inserted after the abdomen is distended using carbon dioxide pneumoperitoneum. The entire surgery is performed laparoscopically (Zhang 2015).

The standard operations are total gastrectomy and subtotal gastrectomy, and are recommended in the presence of nodal involvement or T<sub>2</sub> to T<sub>4a</sub> tumours. Subtotal gastrectomy can be performed when a minimum of 2 to 5 cm proximal cancer-free margin can be achieved, depending upon the depth of infiltration and the growth pattern of the cancer (Japanese Gastric Cancer Association 2011). Proximal gastrectomy can be performed for T<sub>1</sub>N<sub>0</sub> proximal gastric cancers when more than half of the distal stomach can be preserved; and a pylorus-preserving gastrectomy can be performed for T<sub>1</sub>N<sub>0</sub> cancers of the middle third of the stomach when the distal margin of the tumour is at least 4 cm from the pylorus (Japanese Gastric Cancer Association 2011). The extent of lymph node excision, and the method of restoration of continuity of the gastrointestinal tract, are controversial (Japanese Gastric Cancer Association 2011; Memon 2011; Waddell 2013; Xiong 2013). Postoperative chemotherapy is recommended after gastrectomy for resectable gastric cancer (Diaz-Nieto 2013; Waddell 2013).

### How the intervention might work

For many surgical procedures, laparoscopic surgery is currently preferred over open surgery. This includes surgical procedures such as cholecystectomy (removal of gallbladder), colon cancer, and hysterectomy (Bijen 2009; Keus 2006; Reza 2006; Talseth 2014; Walsh 2009). The reason for this preference of laparoscopic surgery over open surgery is because of decreased pain, decreased blood loss, shorter hospital stay, earlier postoperative recovery, better cosmesis (physical appearance), and decreased costs (Bijen 2009; Keus 2006; Reza 2006; Talseth 2014; Walsh 2009).

### Why it is important to do this review

While the smaller incision and earlier postoperative recovery appear to be potential advantages of laparoscopic gastrectomy or laparoscopy-assisted gastrectomy, the safety of the laparoscopic approach (for a procedure that has a high complication rate) and cancer clearance after laparoscopic and laparoscopy-assisted gastrectomy has to be ensured before the method can be widely recommended. There are concerns about cancer clearance, since port site metastases (recurrence of cancer at the laparoscopic port site) have been reported after many cancers (Kais 2014; Palomba 2014; Song 2014). Animal research has shown that the increased intra-abdominal pressure during laparoscopy (pneumoperitoneum) may drive the malignant cells into ports, resulting in seeding of the port site and port site metastases (Hopkins 1999). Another reason is that the malignant cells may be adherent to the laparoscopic instruments that are introduced and removed through the ports, resulting in seeding of the port site and port site metastases (Hopkins 1999). Another issue is the adequacy of cancer clearance in terms of resection margins and the extent of lymph nodes removed with laparoscopy. Therefore, oncological safety (cancer clearance) is an important issue with laparoscopic and laparoscopy-assisted gastrectomy. There is no Cochrane review on this topic.

## OBJECTIVES

To assess the benefits and harms of laparoscopic gastrectomy or laparoscopy-assisted gastrectomy versus open gastrectomy for people with gastric cancer. In particular, we planned to investigate the effects by patient groups, such as cancer stage, anaesthetic risk, and body mass index (BMI), and by intervention methods, such as method of anastomosis, type of gastrectomy and laparoscopic or laparoscopically-assisted gastrectomy.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

We included randomised controlled trials (RCTs). We included studies reported as full text, studies published as abstract only, and unpublished data.

#### Types of participants

We included adults undergoing gastrectomy for gastric adenocarcinoma (cancer). We included trials in which separate outcome data for people undergoing gastrectomy for gastric adenocarcinoma were available, even if some of the participants underwent gastrectomy for other causes, including lymphomas.

### Types of interventions

We included trials comparing laparoscopic gastrectomy or laparoscopy-assisted gastrectomy with open gastrectomy, provided that the only difference between the randomised groups was the use of laparoscopic (or laparoscopy-assisted) or open method of access to the stomach. We excluded trials comparing totally laparoscopic gastrectomy with laparoscopy-assisted gastrectomy or different methods of open or laparoscopic gastrectomy. We also excluded any trials comparing robot-assisted gastrectomy with laparoscopic or open gastrectomy.

### Types of outcome measures

#### Primary outcomes

1. Mortality
  - i) Short-term mortality (in-hospital mortality or mortality within three months)
  - ii) Long-term mortality (at maximal follow-up)
2. Serious adverse events (within three months). We accepted the following definitions of serious adverse events.
  - i) Clavien-Dindo classification (Clavien 2009; Dindo 2004): Grade III or more.
  - ii) International Conference on Harmonisation - Good Clinical Practice guideline (ICH-GCP; ICH-GCP 1996): serious adverse events defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, and results in persistent or significant disability/incapacity.
  - iii) Individual complications that could clearly be classified as Grade III or more with the Clavien-Dindo classification (Clavien 2009; Dindo 2004), or as a serious adverse event with the ICH-GCP classification.
3. Health-related quality of life (using any validated scale)
  - i) Short-term (four weeks to three months)
  - ii) Medium-term (more than three months to one year)

#### Secondary outcomes

1. Recurrence (local recurrence, surgical wound recurrence (also called port site metastases in the laparoscopic group) or distal metastases)
  - i) Short-term recurrence (within six months)
  - ii) Long-term recurrence (at maximal follow-up)
2. Adverse events (within three months). We accepted all adverse events reported by the study author irrespective of the severity of the adverse event.
3. Perioperative blood transfusion requirements (during surgery or within one week after surgery) (whole blood or red cell transfusion).
  - i) Proportion of people requiring blood transfusion
  - ii) Quantity of blood transfusion

4. Measures of earlier postoperative recovery
  - i) Length of hospital stay (including the index admission for gastrectomy and any surgical complication-related re-admission)
  - ii) Time to return to normal activity (return to preoperative mobility without any additional carer support)
  - iii) Time to return to work (in people who were employed previously)
5. Positive resection margins (presence of macroscopic or microscopic cancer tissue at the plane of resection) at histopathological examination after surgery.
6. Number of lymph nodes harvested during surgery.

We based the choice of the above clinical outcomes on the necessity to assess whether laparoscopic surgery results in adequate cancer clearance, is safe, and is beneficial in terms of decreased blood transfusion requirements; earlier postoperative recovery allowing earlier discharge from hospital, return to normal activity, and return to work; and improvement in health-related quality of life. We highlight that the positive resection margins at histopathological examination after surgery, and the number of harvested lymph nodes during surgery, are surrogate outcomes, and we have included these in order to explore whether these are responsible for any differences in survival or mortality. We included studies which met the inclusion criteria, irrespective of whether they reported the secondary outcomes.

## Search methods for identification of studies

### Electronic searches

We conducted a literature search to identify all published and unpublished RCTs. The literature search identified potential studies in all languages. We translated the non-English language papers and assessed them fully for potential inclusion in the review as necessary.

We searched the following electronic databases for identifying potential studies.

1. The Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 9) ([Appendix 1](#)).
2. MEDLINE (1966 to September 2015) ([Appendix 2](#)).
3. EMBASE (1988 to September 2015) ([Appendix 3](#)).
4. Science Citation Index (1982 to September 2015) ([Appendix 4](#)).

We also conducted a search of ClinicalTrials.gov ([ClinicalTrials.gov](#); [Appendix 5](#)) and the World Health Organization - International Clinical Trials Registry Platform (WHO ICTRP; [www.who.int/ictrp/en/](#); [Appendix 6](#)). We performed all the searches on 5 September 2015.

### Searching other resources

We checked reference lists of all primary studies and review articles for additional references. We contacted authors of identified trials and asked them to identify other published and unpublished studies.

We searched for errata or retractions from eligible trials on PubMed on 7 October 2015 ([www.ncbi.nlm.nih.gov/pubmed](#)).

## Data collection and analysis

### Selection of studies

Two review authors (LB and KG) independently screened titles and abstracts for inclusion all the potential studies that we identified as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve' (ineligible). We retrieved the full text study reports for coded as 'retrieve' and two review authors (LB and KG) independently screened the full text, identified studies for inclusion, and identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreements through discussion. We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, is the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram ([Moher 2009](#)), and [Characteristics of excluded studies](#) table.

### Data extraction and management

We used a standard data collection form for study characteristics and outcome data that had been piloted on at least one study in the review. Two review authors (LB and KG) extracted study characteristics from included studies and detailed them in a [Characteristics of included studies](#) table. We extracted the following study characteristics.

1. Methods: study design, total duration of the study and run in, number of study centres and location, study setting, withdrawals, and date of study.
2. Participants: number, mean age, gender, tumour stage, tumour location, American Society of Anesthesiologists (ASA) status ([ASA 2014](#)), inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, and concomitant interventions.
4. Outcomes: primary and secondary outcomes specified and collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of trial authors.

Two review authors (LB and KG) independently extracted outcome data from included studies. If outcomes were reported multiple times for the same time frame (for example, short-term health-related quality of life was reported at six weeks and three months),

we chose the later time point (i.e. three months) for data extraction. For time-to-event outcomes where data is censored, we extracted data to calculate the natural logarithm of the hazard ratio (HR) and its standard error using the methods suggested in [Parmar 1998](#).

We included all randomised participants for medium-term and long-term outcomes (e.g. mortality or quality of life), and this was not conditional upon the short-term outcomes (e.g. being alive at three months or having a low or high quality of life index at three months).

We noted in the [Characteristics of included studies](#) table if outcome data are reported in an unusable way. We resolved disagreements by consensus. One review author (LB) copied across the data from the data collection form into Review Manager 5 ([RevMan 2014](#)). We double-checked that the data were entered correctly by comparing the study reports with how the data are presented in the systematic review.

### Assessment of risk of bias in included studies

Two review authors (LB and KG) independently assessed risk of bias for each study using the criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011](#)). We resolved any disagreements by discussion. We assessed the risk of bias according to the following domains.

1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.

We graded each potential source of bias as high, low, or unclear risk of bias and provided a quotation from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised the risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all-cause mortality may be very different from a participant-reported pain scale). Where information on risk of bias related to unpublished data or correspondence with a trial author, we noted this in the 'Risk of bias' table.

We considered trials were at low risk of bias in all domains to be at overall low risk of bias. Other trials were considered to be at unclear or high risk of bias. When considering treatment effects, we took into account the risk of bias for the studies that contribute to that outcome.

### Assessment of bias in conducting the systematic review

We conducted the review according to this published protocol and reported any deviations from it in the [Differences between protocol and review](#) section of the systematic review.

### Measures of treatment effect

We analysed dichotomous data as risk ratios (RRs) with 95% CIs and continuous data as mean differences (MDs) with 95% CIs when the outcome was reported or converted to the same units in all the trials (e.g. hospital stay, time to return to work) or standardised mean differences (SMDs) with 95% CIs when different scales were used for measuring the outcome (e.g. quality of life). We ensured that higher scores for continuous outcomes had the same meaning for the particular outcome, explained the direction to the reader, and reported where the directions were reversed, if this was necessary. We calculated the rate ratio (RaR) with 95% CIs for outcomes such as adverse events and serious adverse events, where it is possible for the same person to develop more than one adverse event (or serious adverse event). We did not identify any studies that reported the RaR of adverse events (or serious adverse events) in the intervention versus control based on Poisson regression. We calculated the HR for time-to-event outcomes such as long-term mortality, long-term recurrence, and time-to-first adverse event (or serious adverse event).

We undertook meta-analyses only where this was meaningful (i.e. if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense).

A common way that trial authors indicate when they have skewed data is by reporting medians and interquartile ranges. When we encountered this, we noted that the data were skewed by following the rough guide for identifying skewed distribution available in the *Cochrane Handbook for Systematic Reviews of Interventions* ([Higgins 2011](#)), and considered the implication of this.

Where multiple trial arms were reported in a single trial, we included only the relevant arms. If two comparisons (e.g. laparoscopy-assisted gastrectomy versus open gastrectomy and totally laparoscopic gastrectomy versus open gastrectomy) had to be entered into the same meta-analysis, we halved the control group to avoid double-counting. The alternative way of including such trials with multiple arms is to pool the results of the laparoscopy-assisted gastrectomy and totally laparoscopic gastrectomy and compare it with open gastrectomy. We performed a sensitivity analysis to determine if the results of the two methods of dealing with multi-arm trials led to different conclusions.

### Unit of analysis issues

The unit of analysis was individual participants undergoing gastrectomy. We did not encounter any cluster-randomised trials for this review, and therefore did not require any specific methodology for this trial type.

## Dealing with missing data

We contacted investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study is identified as abstract only). If we were unable to obtain the information from the investigators or study sponsors, we imputed mean from median (i.e. consider median as the mean) and standard deviation from standard error, interquartile range, or P values according to the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011), but assessed the impact of including such studies in a sensitivity analysis. If we were unable to calculate the standard deviation from the standard error, interquartile range, or P values, we imputed the standard deviation as the highest standard deviation in the remaining trials included in the outcome, fully aware that this method of imputation will decrease the weight of the studies in the meta-analysis of MD and shift the effect towards no effect for SMD.

## Assessment of heterogeneity

We used the  $I^2$  statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity as per the *Cochrane Handbook for Systematic Reviews of Interventions* (i.e. greater than 50% to 60%; Higgins 2011), we explored it by pre-specified subgroup analysis.

## Assessment of reporting biases

We attempted to contact study authors, asking them to provide missing outcome data. Where this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results using a sensitivity analysis.

If we were able to pool more than 10 trials, we created and examined a funnel plot to explore possible publication biases. We used Egger's test to determine the statistical significance of the reporting bias (Egger 1997). We considered a P value less than 0.05 statistically significant for reporting bias.

## Data synthesis

We performed analyses using Review Manager 5 (RevMan 2014).

## Subgroup analysis and investigation of heterogeneity

We planned to carry out the following subgroup analyses.

1. Totally laparoscopic and laparoscopy-assisted gastrectomy.
2. Different cancer stages (early gastric cancer and advanced gastric cancer; node-positive and node-negative gastric cancer). For this, we defined early gastric cancer as tumours confined to mucosa and submucosa, irrespective of lymph node metastasis (Japanese Gastric Cancer Association 2011).
3. Different types of gastrectomy (proximal, pylorus-preserving, subtotal, total gastrectomy).

4. Different methods of anastomoses (stapler versus hand-sewn anastomoses).

5. People with different anaesthetic risk (ASA I (a healthy person) or ASA II (a person with mild systemic disease) versus ASA III or more (a person with severe systemic disease or worse).

6. Different body mass index (BMI) (healthy weight (BMI 18.5 to 25) versus overweight or obese (BMI 25 or greater).

We used all primary outcomes in subgroup analyses.

We used the formal  $\text{Chi}^2$  test for subgroup differences to test for subgroup interactions.

## Sensitivity analysis

We performed sensitivity analyses defined a priori, to assess the robustness of our conclusions. These involved:

1. excluding trials at unclear or high risk of bias (one of more of the risk of bias domains (other than blinding of surgeon) classified as unclear or high);
2. excluding trials in which either mean or standard deviation, or both are imputed;
3. excluding cluster-RCTs in which the adjusted effect estimates are not reported; and
4. different methods of dealing with multi-arm trials (see [Measures of treatment effect](#)).

## 'Summary of findings' table

We created two 'Summary of findings' tables. [Summary of findings for the main comparison](#) includes all of the pre-specified primary outcomes that have been reported in the studies (short-term mortality, long-term mortality, and serious adverse events); [Summary of findings 2](#) includes all of the pre-specified secondary outcomes that have been reported in the studies (long-term recurrence, adverse events, perioperative blood transfused, length of hospital stay, and number of lymph nodes harvested). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it related to the studies that contributed data to the meta-analyses for the pre-specified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011), and using GRADEproGDT software (GRADEproGDT 2015). We justified all decisions to downgrade or upgrade the quality of studies using footnotes and made comments to aid reader's understanding of the review, where necessary. We considered whether there was any additional outcome information that we were unable to incorporate into the meta-analyses, noted this in the comments, and stated if it supported or contradicted the information from the meta-analyses.

## Reaching conclusions

We based our conclusions only on findings from the quantitative or narrative synthesis of included studies for this review. We avoided



making recommendations for practice, and our [Implications for research](#) will give the reader a clear sense of where the focus of any future research in the area should be, and what the remaining uncertainties are.

## RESULTS


### Description of studies

#### Results of the search

We identified 18,369 references through electronic searches of the Cochrane Central Register of Controlled trials (CENTRAL),

MEDLINE, EMBASE, Science Citation Index, ClinicalTrials.gov and WHO ICTRP (World Health Organization International Clinical Trials Registry Platform). After completion of manually removing duplicate references there were 11,953 references. We excluded 11,914 clearly irrelevant references through reading the abstracts. We sought 42 references in full text for further assessment. We did not identify any additional references to trials by searching the trial registry. We excluded 13 references (11 studies or comments) because of the reasons mentioned in the [Characteristics of excluded studies](#) tables and [Excluded studies](#). We excluded five references (three trials) which were protocols of ongoing trials with no interim results available. Thirteen trials (24 references) met the inclusion criteria and were included in this review ([Aoyama 2014](#); [Cai 2011](#); [Chen Hu 2012](#); [Deng 2009](#); [Hayashi 2005](#); [Hu 2015](#); [Huscher 2005](#); [Kim 2013](#); [Kim 2015](#); [Kitano 2002](#); [Lee 2005](#); [Sakuramoto 2013](#); [Takiguchi 2013](#)). The reference flow diagram is shown in [Figure 1](#).

**Figure 1. Study flow diagram.**



## Included studies

The thirteen trials compared laparoscopic with open gastrectomy (Aoyama 2014; Cai 2011; Chen Hu 2012; Deng 2009; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2013; Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013). Twelve of the trials were two-armed RCTs (Aoyama 2014; Cai 2011; Deng 2009; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2013; Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013). The thirteenth was a four-armed trial (Chen Hu 2012). Two of the arms involved laparoscopic surgery (fast-track laparoscopic gastrectomy versus standard procedure laparoscopic gastrectomy) and two arms involved open gastrectomy (fast-track laparoscopic gastrectomy versus standard procedure laparoscopic gastrectomy). The exact tumour stages included for each trial are reported in the [Characteristics of included studies](#) tables. Broadly, five trials included patients with early stage gastric cancer (Hayashi 2005; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013), three trials included patients with only advanced gastric cancer (Cai 2011; Kim 2013; Hu 2015), four trials included patients with early or advanced gastric cancer, a wide range of cancer staging (Aoyama 2014; Chen Hu 2012; Huscher 2005; Kim 2015), and one trial did not specify the cancer staging of included patients (Deng 2009).

Four of the trials included patients with an ASA risk score of III (Cai 2011; Hu 2015; Huscher 2005; Kim 2015), one trial did not include patients with ASA risk score III (Sakuramoto 2013), and the remaining eight trials did not specify their inclusion or exclusion (Aoyama 2014; Chen Hu 2012; Deng 2009; Hayashi 2005; Kim 2013; Kitano 2002; Lee 2005; Takiguchi 2013). None of the 13 trials specifically stated the inclusion or exclusion of patients with a BMI greater than 30.

Ten of the studies used laparoscopy-assisted gastrectomy (Aoyama 2014; Cai 2011; Chen Hu 2012; Hayashi 2005; Kim 2013; Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013), with three potentially using the totally laparoscopic method (Deng 2009; Hu 2015; Huscher 2005). There was no mention of an incision to remove the specimen in these trials, and the procedure was termed laparoscopic gastrectomy in these trials. However, it should be noted that some trials which were really laparoscopy-assisted gastrectomy (based on the description of the procedure) reported the procedure as laparoscopic gastrectomy. So, it is not clear whether any of the trials used totally laparoscopic gastrectomy.

Twelve of the trials involved patients in whom subtotal (distal) gastrectomy was performed (Aoyama 2014; Chen Hu 2012; Deng 2009; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2013; Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013); in Cai 2011, proximal, distal or total gastrectomy was per-

formed. D1 nodal dissection was performed in both groups in one trial (Hayashi 2005). D2 nodal dissection was performed in both groups in four trials (Cai 2011; Deng 2009; Hu 2015; Kim 2013). D1 or more nodal dissections were performed in both groups in three trials (Aoyama 2014; Huscher 2005; Kim 2015). In two trials, selected groups of lymph nodes were dissected in both groups (Sakuramoto 2013; Takiguchi 2013). In one trial, selected nodes were dissected in the laparoscopic group, while D2 nodal dissection was performed in the open group (Lee 2005). Information on nodal dissection was not available in two trials (Chen Hu 2012; Kitano 2002). Seven of the trials used the Billroth I method of anastomosis alone (Aoyama 2014; Deng 2009; Hayashi 2005; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013), four of the trials used either the Billroth I or II anastomosis, Roux en Y anastomosis, oesophagogastrostomy or oesophageal jejunostomy (Cai 2011; Chen Hu 2012; Huscher 2005; Kim 2015), and two did not state the method of anastomosis used (Hu 2015; Kim 2013). Five trials used staples as the anastomotic method (Aoyama 2014; Hayashi 2005; Lee 2005; Sakuramoto 2013; Takiguchi 2013). In the remaining trials, either a combination of stapler and hand-sewn anastomosis were used (Huscher 2005), or the information on stapler versus hand-sewn anastomosis was not available (Cai 2011; Chen Hu 2012; Deng 2009; Hu 2015; Kim 2013; Kim 2015; Kitano 2002). Drains were routinely used in both groups in one trial (Sakuramoto 2013), and no routine drains were used in either group in one trial (Aoyama 2014). In one 2 x 2 factorial trial in which the safety and effectiveness of laparoscopic versus open gastrectomy and fast-track surgery versus conventional surgery, drains were used in participants who underwent fast-track surgery in both the laparoscopic and open groups (Chen Hu 2012). Two trials reported drains being used in the laparoscopic gastrectomy group, but did not report whether drains were used routinely in the open gastrectomy group (Lee 2005; Takiguchi 2013). The information on drain use was not available in the remaining trials (Cai 2011; Deng 2009; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2013; Kim 2015; Kitano 2002).

The follow-up period was not available for one trial (Hu 2015).

The follow-up period in the remaining trials were as follows.

- Until discharge (Deng 2009; Sakuramoto 2013)
- 30 days (Aoyama 2014; Chen Hu 2012; Kim 2013; Kim 2015).
- 14 months (Lee 2005); 22 months (Cai 2011); 26 months (Kitano 2002).
- 42 months (Hayashi 2005); 52 months (Huscher 2005); 60 months (Takiguchi 2013).

In total, 2794 participants were randomised in the 13 trials included in this review. One trial which included 53 participants did not contribute any data for this review, because none of the outcomes included in the review were reported (Deng 2009). Two



hundred and thirteen participants were excluded in the remaining 12 trials that contributed data, leaving a total of 2528 participants for whom data were available. Of these 2528 participants, 1288 were randomised to laparoscopic gastrectomy and 1240 to open gastrectomy (Aoyama 2014; Cai 2011; Chen Hu 2012; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2013; Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013).

### Excluded studies

We excluded a total of 13 references (11 studies or comments). We excluded three references because they were reports of a 'quasi-randomised' control trial in which block allocation equivalent to alternate assignment was used (Kim 2008). We excluded two ref-


erences because they were comments on Kim 2008 (Kim 2009; Liakakos 2009), and we excluded one reference because it was an editorial (Kanellos 2009). We excluded seven references because they were not RCTs (Han 2014; Kawamura 2008; Lee 2008; Lee 2009; Li 2014; Lin 2014; Sakuramoto 2009).

We excluded five other references because they were protocols for three trials which have not yet reported the results (Haverkamp 2015; Straatman 2015; Yoshikawa 2012). A summary of these trials is reported in Characteristics of ongoing studies.

### Risk of bias in included studies

All the trials were at unclear or high risk of bias as shown in Figure 2 and Figure 3.

**Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**



**Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.**

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Aoyama 2014	+	+	?	?	?	+	+
Cai 2011	?	?	?	?	-	+	+
Chen Hu 2012	?	?	-	?	-	+	+
Deng 2009	?	?	?	?	?	-	+
Hayashi 2005	?	+	-	?	+	+	+
Hu 2015	?	?	-	-	+	-	+
Huscher 2005	?	?	?	?	-	+	+
Kim 2013	+	+	-	?	-	-	+
Kim 2015	+	+	?	?	-	-	+
Kitano 2002	?	+	?	?	?	-	+
Lee 2005	+	?	?	?	?	-	-
Sakuramoto 2013	+	+	-	-	-	-	+
Takiguchi 2013	?	+	-	-	+	-	+

## Allocation

Four trials were free from selection bias (Aoyama 2014; Kim 2013; Kim 2015; Sakuramoto 2013). These trials had a low risk of bias in random sequence generation and allocation concealment. The remaining trials had unclear risk of bias in at least one of the aspects of random sequence generation or allocation concealment.

## Blinding

Seven of the trials were at unclear risk of performance bias because of a lack of reported information (Aoyama 2014; Cai 2011; Deng 2009; Huscher 2005; Kim 2015; Kitano 2002; Lee 2005), with the remaining six being at high risk of performance bias, with patients and healthcare providers not being blinded (Chen Hu 2012; Hayashi 2005; Hu 2015; Kim 2013; Sakuramoto 2013; Takiguchi 2013).

Ten of the trials were at unclear risk of detection bias because of a lack of reported information (Aoyama 2014; Cai 2011; Chen Hu 2012; Deng 2009; Hayashi 2005; Huscher 2005; Kim 2013; Kim 2015; Kitano 2002; Lee 2005), with the remaining three being at high risk of detection bias, with outcome assessors not being blinded (Hu 2015; Sakuramoto 2013; Takiguchi 2013).

## Incomplete outcome data

We classified three trials at low risk of attrition bias as they described no post-randomisation drop-outs (Hayashi 2005; Hu 2015; Takiguchi 2013). Four trials were at unclear risk of attrition bias as the reports did not describe the participant flow clearly (Aoyama 2014; Deng 2009; Kitano 2002; Lee 2005). Six trials were at high risk of attrition bias as they had post-randomisation drop-outs which were likely to affect the effect estimates (Cai 2011; Chen Hu 2012; Huscher 2005; Kim 2013; Kim 2015; Sakuramoto 2013).

## Selective reporting

We classified six of the trials at low risk of reporting bias, with both postoperative mortality and morbidity reported (Aoyama 2014; Cai 2011; Chen Hu 2012; Hayashi 2005; Huscher 2005; Sakuramoto 2013). We classified seven of the trials at high risk of reporting bias, as one or both of these were not reported (Deng 2009; Hu 2015; Kim 2013; Kim 2015; Kitano 2002; Lee 2005; Takiguchi 2013).

## Other potential sources of bias

In one trial, a more extensive procedure (subtotal gastrectomy) was performed in open gastrectomy group compared to laparoscopic group (distal gastrectomy) (Lee 2005). This could potentially favour the laparoscopic group in terms of decreased complications, but favour the open group in terms of decreased long-term recurrence and mortality. We did not detect any other sources of bias in the remaining trials.

## Effects of interventions

See: **Summary of findings for the main comparison** Laparoscopic gastrectomy compared to open gastrectomy for gastric cancer (primary outcomes); **Summary of findings 2** Laparoscopic gastrectomy compared to open gastrectomy for gastric cancer (secondary outcomes)

The outcomes reported in these trials were: short-term mortality, long-term mortality, serious adverse events within three months, short-term recurrence, long-term recurrence, adverse events within three months, blood transfusion during or within a week of surgery, quantity of perioperative blood transfused, length of hospital stay, positive resection margins on histopathology, and number of lymph nodes harvested. The remaining outcomes of interest in the review, i.e. short- and medium-term health-related quality of life, time to return to normal activity, and time to return to work were not reported in any of the trials. The results are partially summarised in **Summary of findings for the main comparison** and **Summary of findings 2**.

### Short-term mortality

Eleven trials reported short-term mortality which is defined as mortality in hospital or within thirty days of treatment (Aoyama 2014; Cai 2011; Chen Hu 2012; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013). We pooled the trials using a fixed-effect model. There was no significant difference in the proportion of participants who died within 30 days of treatment between laparoscopic gastrectomy (7/1188: adjusted proportion (based on meta-analysis) = 0.6%) and open gastrectomy (4/1447: 0.3%) (RR 1.60, 95% CI 0.50 to 5.10; participants = 2335; studies = 11;  $I^2 = 0\%$ ; low quality evidence) (**Analysis 1.1**; **Summary of findings for the main comparison**). There was no change to the conclusions when we used a random-effects model or when we calculated the risk difference (RD 0.00, 95% CI -0.01 to 0.01; participants = 2335; studies = 11;  $I^2 = 0\%$ ).

### Long-term mortality

Three trials reported long-term mortality (Cai 2011; Huscher 2005; Takiguchi 2013). In one of these trials, all the participants

were alive after a follow-up period of 60 months (Takiguchi 2013). We pooled the trials using a fixed-effect model. There was no significant difference in long-term mortality between the groups (HR 0.94, 95% CI 0.70 to 1.25; participants = 195; studies = 3;  $I^2 = 0\%$ ; very low quality evidence) (Analysis 1.2; Summary of findings for the main comparison). There was no change to the conclusions when we used a random-effects model. Approximately 55% to 60% of participants were alive after about 52 months (Huscher 2005).

### Serious adverse events within three months

Eight trials reported serious adverse events within three months of treatment (Aoyama 2014; Cai 2011; Chen Hu 2012; Hayashi 2005; Huscher 2005; Kitano 2002; Lee 2005; Sakuramoto 2013). The serious adverse events in the trials included anastomotic leakage, anastomotic stenosis requiring balloon dilatation, pancreatic fistula, pancreatic injury, small bowel volvulus requiring adhesiolysis, bleeding requiring reoperation, abdominal abscess, myocardial infarction, acute respiratory distress syndrome, pleural effusion requiring puncture, and pneumonia. The type of serious adverse events were similar in nature between the groups. We pooled the trials using a fixed-effect model. There was no significant difference in the proportion of participants who suffered a serious adverse event between laparoscopic gastrectomy (7/216: adjusted proportion = 3.6%) and open gastrectomy (13/216: 6%) within three months of treatment (RR 0.60, 95% CI 0.27 to 1.34; participants = 432; studies = 8;  $I^2 = 0\%$ ; very low quality evidence) (Analysis 1.3; Summary of findings for the main comparison). There was no change to the conclusions when we used a random-effects model or when we calculated risk difference.

### Health-related quality of life

Short- and medium-term health-related quality of life were not reported in any of the trials.

### Short-term recurrence

Three trials reported short-term recurrence, which is defined as local recurrence, surgical wound recurrence or distal metastases within six months (Hayashi 2005; Kitano 2002; Lee 2005). No events were reported for either laparoscopic (52 participants) or open gastrectomy (51 participants). Therefore, we could not calculate an effect estimate (participants = 103; studies = 3) (Analysis 1.4).

### Long-term recurrence

Four trials reported long-term recurrence (> six months) (Hayashi 2005; Huscher 2005; Kitano 2002; Lee 2005). Three of these three trials did not report any recurrence in either group (Hayashi

2005; Kitano 2002; Lee 2005). There was no significant difference in the hazard ratio for recurrence more than six months after treatment between the two groups (HR 0.95, 95% CI 0.70 to 1.30; participants = 160; studies = 4; very low quality evidence) (Analysis 1.5; Summary of findings 2). Since only one trial contributed to the analysis, the issue of fixed-effect versus random-effects meta-analysis and assessment of heterogeneity did not arise.

### Adverse events within three months

Eleven trials reported adverse events within three months of treatment (Aoyama 2014; Cai 2011; Chen Hu 2012; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2013; Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013). We pooled the trials using a random-effects model. There were significantly fewer adverse events following laparoscopic gastrectomy (204/268: adjusted proportion = 16.1%) versus open gastrectomy (253/1222: 20.7%) (RR 0.78, 95% CI 0.60 to 1.01; participants = 2490; studies = 11;  $I^2 = 38\%$ ; very low quality evidence) (Analysis 1.6; Summary of findings 2). However, on using the fixed-effect model, there was no statistically significant difference between the groups (RR 0.78, 95% CI 0.66 to 0.92; participants = 2490; studies = 11;  $I^2 = 38\%$ ). Two large trials had narrow confidence intervals and had results in opposite directions, and this may account for the differences between the fixed-effect and random-effects models. In addition, we performed a sensitivity analysis excluding Lee 2005, in which the laparoscopic group underwent a less invasive procedure than the open group. There was no change in the results by excluding this trial.

### Blood transfusion during or within a week of surgery

Two trials reported the proportion of patients requiring blood transfusion during or within a week of surgery (Aoyama 2014; Takiguchi 2013). None of the participants in either group in either of the trials required a blood transfusion. Therefore, we could not estimate an effect estimate (participants = 66; studies = 2) (Analysis 1.7). Since both trials reported the mean and standard deviation, we did not perform any sensitivity analysis excluding studies in which standard deviation was imputed.

### Quantity of perioperative blood transfused

Two trials reported quantity of perioperative blood transfused (Cai 2011; Lee 2005): Lee 2005 reported the number of units of blood transfused; and Cai 2011 reported the amount of blood transfused in SI units. We pooled the trials using a fixed-effect model. There was no significant difference in the amount of blood transfused between the laparoscopic and open gastrectomy groups (SMD 0.05, 95% CI -0.27 to 0.38; participants = 143; studies = 2;  $I^2 = 0\%$ ; very low quality evidence) (Analysis 1.8; Summary of findings 2). There was no change to the conclusions when we used a random-effects model.

### Length of hospital stay

Eight trials reported length of hospital stay (Cai 2011; Chen Hu 2012; Hayashi 2005; Huscher 2005; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013). The length of hospital stay was significantly shorter in the laparoscopic group than the open group (MD -1.38 days, 95% CI -2.57 to -0.19; participants = 444; studies = 8;  $I^2 = 76\%$ ; very low quality evidence) using the random-effects model (Analysis 1.9; Summary of findings 2). There was substantial heterogeneity as noted by  $I^2$  of 76% and  $\text{Chi}^2$  test for heterogeneity P value of 0.0001. Using the fixed-effect model did not alter the results (MD -0.86 days, 95% CI -1.27 to -0.44; participants = 444; studies = 8;  $I^2 = 76\%$ ). In two trials, median hospital stay rather than mean hospital stay was reported (Chen Hu 2012; Takiguchi 2013). In Takiguchi 2013, the standard deviation was calculated from the P value, while in Chen Hu 2012, the standard deviation was imputed as the highest standard deviation from the remaining trials. Excluding these two trials, there was no statistically significant difference between the two groups (MD -1.82 days, 95% CI -3.72 to 0.07; participants = 319; studies = 6;  $I^2 = 83\%$ ) using the random-effects model, although there was still a statistically significant difference between the groups using the fixed-effect model (MD -0.68 days, 95% CI -1.31 to -0.06; participants = 319; studies = 6;  $I^2 = 83\%$ ). The exclusion of Lee 2005, in which the laparoscopic group underwent a less invasive procedure did not alter the results.

### Time to return to normal activity

This outcome was not reported in any of the trials.

### Time to return to work

This outcome was not reported in any of the trials.

### Positive resection margins at histopathological examination

One trial reported the number of patients with positive resection margins at histopathological examination (Kitano 2002). No events were reported for either laparoscopic or open gastrectomy. Therefore, we could not calculate an effect estimate (participants = 28; study = 1) (Analysis 1.10).

### Number of lymph nodes harvested

Nine trials reported the number of lymph nodes harvested (Aoyama 2014; Cai 2011; Chen Hu 2012; Hayashi 2005; Huscher 2005; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013). We analysed the trials using a fixed-effect model. There was no significant difference in the number of lymph nodes harvested between the two groups (MD -0.63, 95% CI -1.51 to 0.25; participants = 472; studies = 9;  $I^2 = 40\%$ ; very low quality evidence) (Analysis 1.11; Summary of findings 2). There was no

change to the conclusions when we used a random-effects model. Since higher numbers of lymph nodes harvested is a better surgical marker, we switched the direction of the X-axis in Analysis 1.11, with trials to the left of the equivalence line favouring open gastrectomy. The mean or standard deviation or both were calculated from other information such as median, standard error, or P value or imputed from the maximum standard deviation in the included studies in four trials (Aoyama 2014; Chen Hu 2012; Huscher 2005; Takiguchi 2013). Excluding these trials did not alter the conclusions (MD -0.62, 95% CI -1.55 to 0.31; participants = 262; studies = 5;  $I^2 = 70\%$ ).

### Subgroup analysis

Of the planned subgroup analyses for the primary outcomes, only two were possible.

1. Different cancer stages (early gastric cancer and advanced gastric cancer). There was no short-term mortality or long-term mortality in laparoscopic or open gastrectomy groups in the early gastric cancer subgroup. So, we could not perform tests for subgroup differences (Analysis 2.1; Analysis 2.2). The test for subgroup differences was not statistically significant for subgroup analysis of serious adverse events, and there was a good overlap of confidence interval between the effect estimates of the different subgroups (Analysis 2.3).

2. Different types of gastrectomy (subtotal versus total gastrectomy). Of the 13 trials, 12 trials reported the use of subtotal gastrectomy (Aoyama 2014; Chen Hu 2012; Deng 2009; Hayashi 2005; Hu 2015; Huscher 2005; Kim 2013; Kim 2015; Kitano 2002; Lee 2005; Sakuramoto 2013; Takiguchi 2013). In Cai 2011, a mixture of different types of gastrectomies was performed. No separate data were available for the different types of gastrectomies. Excluding this trial did not alter the results (Analysis 2.4; Analysis 2.5; Analysis 2.6).

The remaining subgroup analyses were not possible for the following reasons.

1. Totally laparoscopic and laparoscopy-assisted gastrectomy: it was not clear whether any of the trials used totally laparoscopic gastrectomy.

2. Different cancer stages (node-positive and node-negative gastric cancer): none of the trials reported the results separately for different nodal status.

3. Different methods of anastomoses (stapler versus hand-sewn anastomoses): five trials used staples as the anastomotic method (Aoyama 2014; Hayashi 2005; Lee 2005; Sakuramoto 2013; Takiguchi 2013). In the remaining trials, either a combination of stapler and hand-sewn anastomosis were used (Huscher 2005), or the information on stapler versus hand-sewn anastomosis was not available (Cai 2011; Chen Hu 2012; Deng 2009; Hu 2015; Kim 2013; Kim 2015; Kitano 2002).

4. People with different anaesthetic risk (ASA I (a healthy person) or ASA II (a person with mild systemic disease) versus

ASA III or more (a person with severe systemic disease or worse): none of the trials that included ASA III participants reported the results separately for ASA III participants.

5. Different BMI (healthy weight (BMI 18.5 to 25) versus overweight or obese (BMI 25 or greater)): none of the trials reported results separately for people with different BMI ranges.

### **Sensitivity analysis**

The sensitivity analysis excluding trials in which either mean or standard deviation or both were imputed have been presented in the individual outcomes. Another sensitivity analysis excluding the trial in which the laparoscopic group underwent less invasive distal gastrectomy, and the open group underwent more invasive subtotal gastrectomy, did not alter the results. We performed the remaining sensitivity analyses for the following reasons.

1. All trials were at unclear or high risk of bias.

2. No cluster-RCTs were included.

3. The only multi-armed trial included was investigating fast-track surgery. Since this variable was not of interest to this review, we considered the trial a two-arm trial.

### **Reporting bias**

Only two outcomes had 10 or more trials, namely, short-term mortality and adverse events. We did not assess reporting bias using a funnel plot in the remaining comparisons. In the outcome, short-term mortality, only three trials had one or more events in at least one of the groups (Hu 2015; Huscher 2005; Kim 2015). So, we did not assess reporting bias using a funnel plot for short-term mortality either. Visual inspection revealed that studies with large variance were more prevalent in the laparoscopic group than the open group, suggesting potential reporting bias. However, the Egger's test was not statistically significant ( $P = 0.3144$ ).

## ADDITIONAL SUMMARY OF FINDINGS *[Explanation]*

Laparoscopic gastrectomy compared to open gastrectomy for gastric cancer (secondary outcomes)						
<b>Patient or population:</b> patients with gastric cancer <b>Settings:</b> secondary or tertiary setting <b>Intervention:</b> laparoscopic gastrectomy <b>Comparison:</b> open gastrectomy						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Open gastrectomy	Laparoscopic gastrectomy				
Long-term recurrence (maximal follow-up)	450 per 1000	433 per 1000 (342 to 540)	HR 0.95 (0.70 to 1.30)	162 (4 studies)	⊕○○○ very low <sup>1,2</sup>	
Proportion with an adverse event (<3 months)	207 per 1000	161 per 1000 (124 to 209)	RR 0.78 (0.60 to 1.01)	2490 (11 studies)	⊕○○○ very low <sup>1,3</sup>	
Quantity of perioperative blood transfused	The mean quantity of perioperative blood transfused in the control groups was <b>0.08 litres</b>	The mean quantity of perioperative blood transfused in the intervention groups was <b>0.05 standard deviations higher</b> (0.27 lower to 0.38 higher)		143 (2 studies)	⊕○○○ very low <sup>1,2</sup>	SMD 0.05 (-0.27 to 0.38)
Length of hospital stay		The mean length of hospital stay in the intervention groups was <b>1.82 lower</b> (3.72 lower to 0.07 higher)		319 (6 studies)	⊕○○○ very low <sup>1,2,4</sup>	

<b>Number of lymph nodes harvested</b>	The mean number of lymph nodes harvested in the control groups was <b>27</b>	The mean number of lymph nodes harvested in the intervention groups was <b>0.63 lower</b> (1.51 lower to 0.25 higher)	472 (9 studies)	⊕○○○ <b>very low</b> <sup>1,4</sup>
--	--	---	--------------------	--

There were no events in either group for short-term recurrence (103 participants (3 studies)), proportion requiring blood transfusion (66 participants (2 studies)), proportion with positive resection margin (incomplete cancer resection) (14 participants (1 study))

None of the trials reported on measures of earlier postoperative recovery such as time to return to normal activity or time to return to work

\*The basis for the **assumed risk** was the mean control group proportion. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** confidence interval; **HR:** hazard ratio; **RR:** risk ratio; **SMD:** standardised mean difference.

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup> There was unclear or high risk of bias within the trials (downgraded by two levels). Please see [Figure 2](#) and [Figure 3](#) which show this.

<sup>2</sup> The confidence intervals were wide (overlaps no effect and clinically significantly effect) and the sample size was small (downgraded by two levels).

<sup>3</sup> Visual inspection revealed that studies with large variance were more in the favour of laparoscopic group than the open group, suggesting potential reporting bias (downgraded by one level).

<sup>4</sup> Significant heterogeneity detected in the studies by the  $I^2$  values and  $\text{Chi}^2$  test (downgraded by two levels).



## DISCUSSION

### Summary of main results

In this review, we compared laparoscopic versus open gastrectomy for people with non-metastatic gastric cancer. There were no statistically significant differences in short-term mortality, long-term mortality, proportion of people with serious adverse events within three months of surgery, proportion of people with recurrence within six months, proportion of people with recurrence after six months, proportion of people requiring blood transfusion during or within a week of surgery, proportion of people with any adverse event within three months of surgery, quantity of perioperative blood transfused, proportion of people with positive resection margins at histopathological examination, or in the number of lymph nodes harvested by each technique. None of the trials reported patient oriented outcomes such as health-related quality of life, time to return to normal activity, or time to return to work. Short-term mortality was reported in 2335 participants. Based on the number of participants included and the confidence intervals obtained by calculating the risk difference, it appears that there is no difference between laparoscopic and open gastrectomy in terms of mortality (i.e. this is lack of effect rather than lack of evidence of effect), although the risk of bias in the trials, mainly due to exclusion of participants who did not receive the planned treatment, introduces some doubt on this issue. Differences in serious adverse events within three months, length of hospital stay, long-term recurrence, and long-term mortality (which are the other major outcomes of interest for patients and healthcare funders) cannot be ruled out since the confidence intervals were wide.

### Overall completeness and applicability of evidence

This review included participants undergoing either laparoscopic or open gastrectomy for gastric cancer. Although the American Society of Anesthesiologists (ASA) status was not reported in many trials, all the participants must have been fit for major surgery since both arms involve major surgeries. Thus, the results of this review are applicable only to patients with gastric cancer, with a variety of stages from early to advanced cancer, and are not applicable to patients who are not suitable for surgery either because of their anaesthetic risk or because of the location or presence of metastatic disease. It should also be noted that the results apply only to laparoscopy-assisted distal gastrectomy since it was not clear whether three trials that did not report a small laparotomy incision performed totally laparoscopic gastrectomy, and because most trials in this review included participants undergoing distal gastrectomy.

### Quality of the evidence

All the trials were at unclear or high risk of bias. Selection bias and funding bias were at unclear or low risk of bias in all trials. Those trials with unclear risk of bias were generally due to a lack of clear information. We graded both performance and detection bias as high risk of bias in a significant number of trials, with issues in blinding of the healthcare providers responsible for these. There was significant bias due to missing outcomes in the trials, with six of the studies at high risk of bias because of post-randomisation drop-outs. This can be easily avoided by using an intention-to-treat analysis, which involves reporting the outcomes for all randomised patients even if they do not receive the relevant treatment. There was significant selective reporting bias in the trials, with seven of the studies at high risk of bias generally because morbidity was not reported adequately. Severity of the outcomes is more important than stating whether an adverse event occurred.

There was significant heterogeneity in length of hospital stay. Because of the few trials included in each subgroup, the subgroup analysis may not be reliable and multiple subgroup analyses can lead to spurious results. A potential reason for this heterogeneity may be different criteria for discharging patients who had undergone gastrectomy in different trials. The trials did not report this sufficiently to determine if this was the reason for the differences in effect estimates in trials.

There was imprecision in many outcomes despite the inclusion of more than 2500 participants in the various trials included in this review. This was because of selective outcome reporting with trials not reporting even important outcomes such as serious adverse events.

Despite the shortcomings in the studies included in this review, these studies constitute the best level of evidence that is currently available. Overall, the evidence from this systematic review is more trustworthy than observational studies and expert opinions. This is because observational studies contain inherent bias. It is quite possible that people with lower tumour burden will be selected to undergo laparoscopic gastrectomy while those with greater tumour burden will undergo open gastrectomy. This will lead to bias due to confounding in observational studies.

### Potential biases in the review process

We followed the *Cochrane Handbook for Systematic Reviews of Interventions* for this review (Higgins 2011). There were no language, publication status, or sample size restrictions. Thus, we minimised the bias due to selection of trials. There was suspicion of reporting bias for adverse events by visual inspection of funnel plots, although this was not substantiated by Egger's test. Since there was no restriction on the publication date, we included trials from the pre-mandatory trial registration era. There is a possibility that some of the trials were not reported because of the direction of results. However, we have to be pragmatic and accept that it will

be difficult to obtain useful data from these trials after such a long period of time. So, we have to arrive at conclusions based on the trials which have been published or reported in conferences. We calculated the hazard ratio for long-term mortality and long-term recurrence using methods suggested in Parmar 1998. This assumes constant proportional hazards. From the Kaplan-Meier curves in the studies, the proportional hazards appeared constant for both long-term mortality and long-term recurrence.

## Agreements and disagreements with other studies or reviews

This is the first Cochrane review to assess laparoscopic versus open gastrectomy for gastric cancer. We identified three previous systematic reviews of RCTs on this topic (Jiang 2013; Liang 2011; Sun 2012). The authors of these systematic reviews appear to suggest that laparoscopic surgery is better than open surgery for one or more short-term outcomes, in particular, length of hospital stay. However, we are more cautious in concluding that laparoscopic surgery is better than open surgery because of the risk of bias in the studies included and the heterogeneity in the length of hospital stay.

## AUTHORS' CONCLUSIONS

### Implications for practice

Based on low quality evidence, there is no difference in short-term mortality between laparoscopic and open gastrectomy. Based on

very low quality evidence, there is no evidence for any differences in short-term or long-term outcomes between laparoscopic and open gastrectomy. However, the data are sparse and the confidence intervals were wide suggesting that significant benefits or harms of laparoscopic gastrectomy cannot be ruled out.

### Implications for research

Several trials are currently being conducted and interim results of these trials have been included in this review. These trials need to perform intention-to-treat analysis to ensure that the results are reliable and report the results according to the CONSORT statement (CONSORT 2010). If new trials are designed, they need to be designed according to the SPIRIT statement (SPIRIT 2013).

## ACKNOWLEDGEMENTS

We thank the authors of the trials who provided additional information for this review.

We thank Karin Dearness, Managing Editor, Cochrane Upper Gastrointestinal and Pancreatic Diseases (UGPD) Group for providing administrative and logistical support for the conduct of the current review, and Racquel Simpson, Trials Search Co-ordinator, Cochrane UGPD Group for developing and executing the search strategies.

We thank the peer reviewers, copy editors and Cochrane Editorial Unit for their comments.

## REFERENCES

### References to studies included in this review

#### Aoyama 2014 {published data only}

\* Aoyama T, Yoshikawa T, Hayashi T, Hasegawa S, Tsuchida K, Yamada T, et al. Randomized comparison of surgical stress and the nutritional status between laparoscopy-assisted and open distal gastrectomy for gastric cancer. *Annals of Surgical Oncology* 2014;**21**(6):1983–90.  
Nakamura K, Katai H, Mizusawa J, Yoshikawa T, Ando M, Terashima M, et al. A phase iii study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage Ia/Ib gastric cancer (JCOG0912). *Japanese Journal of Clinical Oncology* 2013;**43**(3):324–7.  
Yoshikawa T, Hayashi T, Aoyama T, Shirai J, Fujikawa H, Ogata T, et al. Randomized comparisons of IL-6 and lean body mass between open versus laparoscopic distal gastrectomy for gastric cancer. *Journal of Clinical Oncology* 2013;**31**(4 Suppl 1):55.

#### Cai 2011 {published data only}

Cai J, Wei D, Gao CF, Zhang CS, Zhang H, Zhao T. A prospective randomized study comparing open versus laparoscopy-assisted D2 radical gastrectomy in advanced gastric cancer. *Digestive Surgery* 2011;**28**(5-6):331–7.

#### Chen Hu 2012 {published data only}

Chen Hu J, Xin Jiang L, Cai L, Tao Zheng H, Yuan Hu S, Bing Chen H, et al. Preliminary experience of fast-track surgery combined with laparoscopy-assisted radical distal gastrectomy for gastric cancer. *Journal of Gastrointestinal Surgery* 2012;**16**(10):1830–9.

#### Deng 2009 {published data only}

Deng HJ, He W, Yu J, Zhang C, Wang YN, Li GX. Effects of laparoscopy-assisted distal gastrectomy on C-reactive protein and visceral proteins in patients with gastric cancer. *Nan Fang Yi Ke Da Xue Xue Bao* 2009;**29**(8):1596–8.

#### Hayashi 2005 {published data only}

Hayashi H, Ochiai T, Shimada H, Gunji Y. Prospective

randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. *Surgical Endoscopy* 2005;**19**(9):1172–6.

**Hu 2015** {published data only}

Hu YF, Huang CM, Sun YH, Su XQ, Li ZY, Xue YW, et al. Laparoscopic d2 distal gastrectomy versus conventional open surgery for advanced gastric cancer: The safety analysis from a multicenter prospective randomized controlled trial in china (CLASS-01 trial). *Journal of Clinical Oncology* 2015;**33**(15 Suppl):1.

**Huscher 2005** {published data only}

\* Huscher CG, Mingoli A, Sgarzini G, Sansonetti A, Di Paola M, Recher A, et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: Five-year results of a randomized prospective trial. *Annals of Surgery* 2005;**241**(2):232–7.

Huscher CGS, Di Paola M, Ponzano C, Sgarzini G, Sansonetti A, Arulampalam T. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: 5-year results of a randomised prospective trial. *British Journal of Surgery* 2005;**92**(S1):159.

**Kim 2013** {published data only}

Kim YW, Nam BH, Yu W, Park YK, Lee JH, Ryu KW, et al. Feasibility study of laparoscopy-assisted D2 distal gastrectomy to treat advanced gastric cancer (COACT-1001); design and rationale. *Surgical Endoscopy* 2012;**26**:S85.

\* Kim YW, Park YK, Yoon HM, Nam BH, Ryu KW, Lee YJ, et al. Result of clinical study on feasibility of laparoscopy-assisted d2 distal gastrectomy to treat advanced gastric cancer (COACT-1001). *Journal of Clinical Oncology* 2013; **31**(15 Suppl 1):Abstract: 4105.

Nam BH, Kim YW, Reim D, Eom BW, Yu WS, Park YK, et al. Laparoscopy assisted versus open distal gastrectomy with D2 lymph node dissection for advanced gastric cancer: Design and rationale of a phase II randomized controlled multicenter trial (COACT 1001). *Journal of Gastric Cancer* 2013;**13**(3):164–71.

**Kim 2015** {published data only}

Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ. Prospective randomized controlled trial (phase III) to comparing laparoscopic distal gastrectomy with open distal gastrectomy for gastric adenocarcinoma (KLASS 01). *Journal of the Korean Surgical Society* 2013;**84**(2):123–30.  
Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, et al. Prospective randomized controlled trial (phase III) to comparing laparoscopic distal gastrectomy with open distal gastrectomy for gastric adenocarcinoma (KLASS 01). *Annals of Surgical Treatment and Research* 2014;**87**(1):51–2.  
Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: An interim report - a phase III multicenter, prospective, randomized trial (KLASS trial). *Annals of Surgery* 2010;**251**(3):417–20.  
\* Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, et al. Morbidity and mortality after laparoscopy-assisted and open distal gastrectomy for stage I gastric

cancer: Results from a multicenter randomised controlled trial (KLASS-01). *Surgical Endoscopy* 2015;**29**:S341.

Lee HJ, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, et al. Morbidity and mortality after laparoscopy-assisted and open distal gastrectomy for stage I gastric cancer: Results from a multicenter randomized controlled trial (KLASS-01). *Journal of Clinical Oncology* 2015;**33**(3 Suppl):4.

Lee JH. A prospective randomized trial comparing totally laparoscopic distal gastrectomy with laparoscopy-assisted distal gastrectomy in early gastric cancer. *Surgical Endoscopy* 2013;**27**:S66.

**Kitano 2002** {published data only}

Fujii K, Sonoda K, Izumi K, Shiraishi N, Adachi Y, Kitano S. T lymphocyte subsets and Th1/Th2 balance after laparoscopy-assisted distal gastrectomy. *Surgical Endoscopy* 2003;**17**(9):1440–4.

\* Kitano S, Shiraishi N, Fujii K, Yasuda K, Inomata M, Adachi Y. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: An interim report. *Surgery* 2002;**131**(1 Suppl):S306–11.

**Lee 2005** {published data only}

Lee JH, Han HS, Lee JH. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: Early results. *Surgical Endoscopy* 2005;**19**(2):168–73.

**Sakuramoto 2013** {published data only}

Sakuramoto S, Yamashita K, Kikuchi S, Futawatari N, Katada N, Watanabe M, et al. Laparoscopy versus open distal gastrectomy by expert surgeons for early gastric cancer in Japanese patients: Short-term clinical outcomes of a randomized clinical trial. *Surgical Endoscopy* 2013;**27**(5):1695–705.

**Takiguchi 2013** {published data only}

Takiguchi S, Fujiwara Y, Yamasaki M, Miyata H, Nakajima K, Sekimoto M, et al. Laparoscopy-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study. *World Journal of Surgery* 2013;**37**(10):2379–86.

## References to studies excluded from this review

**Han 2014** {published data only}

Han SU. Laparoscopy-assisted endoscopic full-thickness resection with basin lymphadenectomy based on sentinel lymph nodes for early gastric cancer. *Journal of the American College of Surgeons* 2014;**219**(3):e29–37.

**Kanellos 2009** {published data only}

Kanellos D, Kanellos I. Impact of laparoscopic D2 gastrectomy on long-term survival for early gastric cancer. *Surgical Endoscopy* 2009;**23**(7):1681–3.

**Kawamura 2008** {published data only}

Kawamura H, Homma S, Yokota R, Yokota K, Watarai H, Hagiwara M, et al. Inspection of safety and accuracy of D2 lymph node dissection in laparoscopy-assisted distal gastrectomy. *World Journal of Surgery* 2008;**32**(11):2366–70.

**Kim 2008** {published data only}

\* Kim YW, Baik YH, Yun YH, Nam BH, Kim DH, Choi IJ, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: Results of a prospective randomized clinical trial. *Annals of surgery* 2008;**248**(5):721–7.

Kim YW, Yoon HM, Yun YH, Nam BH, Eom BW, Baik YH, et al. Long-term outcomes of laparoscopy-assisted distal gastrectomy for early gastric cancer: Result of a randomized controlled trial (COACT 0301). *Surgical Endoscopy* 2013;**27**(11):4267–76.

Yoon HM, Kim YW, Lee JH, Ryu KW, Eom BU, Choi IJ, et al. Long term outcomes of laparoscopy-assisted distal gastrectomy versus open distal gastrectomy for early gastric cancer. *Surgical Endoscopy* 2012;**26**:S2.

**Kim 2009** {published data only}

Kim YW, Yoon H. Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes reply. *Annals of Surgery* 2009;**250**(2):350.

**Lee 2008** {published data only}

Lee SJ, Hyung WJ, Koo BN, Lee JY, Jun NH, Kim SC, et al. Laparoscopy-assisted subtotal gastrectomy under thoracic epidural-general anesthesia leading to the effects on postoperative micturition. *Surgical Endoscopy* 2008;**22**(3):724–30.

**Lee 2009** {published data only}

Lee JH, Yom CK, Han HS. Comparison of long-term outcomes of laparoscopy-assisted and open distal gastrectomy for early gastric cancer. *Surgical Endoscopy* 2009;**23**(8):1759–63.

**Li 2014** {published data only}

Li HT, Han XP, Su L, Zhu WK, Xu W, Li K, et al. Short-term efficacy of laparoscopy-assisted vs open radical gastrectomy in gastric cancer. *World Journal of Gastrointestinal Surgery* 2014;**6**(4):59–64.

**Liakakos 2009** {published data only}

Liakakos T, Roukos DH. Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. *Annals of Surgery* 2009;**250**(2):349–50.

**Lin 2014** {published data only}

Lin W, Li Z, Xu Y, Xie X, Huang Z, Pan G. Comparative study of laparoscopic gastrectomy D2 radical surgery and open gastrectomy for upper stomach cancer. *Cancer Research and Clinic* 2014;**26**(5):332–5.

**Sakuramoto 2009** {published data only}

Sakuramoto S, Kikuchi S, Futawatari N, Katada N, Moriya H, Hirai K, et al. Laparoscopy-assisted pancreas- and spleen-preserving total gastrectomy for gastric cancer as compared with open total gastrectomy. *Surgical Endoscopy* 2009;**23**(11):2416–23.

**References to ongoing studies****Haverkamp 2015** {published data only}

Haverkamp L, Brenkman HJ, Seesing MF, Gisbertz SS, van Berge Henegouwen MI, Luyer MD, et al. Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial). *BMC Cancer* 2015;**15**(1):556.

**Straatman 2015** {published data only}

Straatman J, Cuesta MA, Gisbertz SS, Van Der Peet DL. The stomach trial: Surgical technique, open versus minimally invasive gastrectomy after chemotherapy. *Surgical Endoscopy* 2014;**28**:419.

Straatman J, Cuesta MA, Van Der Peet DL. The stomach trial: Surgical technique, open versus minimally invasive gastrectomy after chemotherapy. *European Journal of Surgical Oncology* 2014;**40**(11):S149–S50.

\* Straatman J, van der Wielen N, Cuesta MA, Gisbertz SS, Hartemink KJ, Alonso Poza A, et al. Surgical techniques, open versus minimally invasive gastrectomy after chemotherapy (STOMACH trial): Study protocol for a randomized controlled trial. *Trials* 2015;**16**(1):123.

**Yoshikawa 2012** {published data only}

Yoshikawa T, Fukunaga T, Taguri M, Kunisaki C, Sakuramoto S, Ito S, et al. Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for operable gastric cancer, a randomized phase ii trial (LANDSCOPE trial). *Japanese Journal of Clinical Oncology* 2012;**42**(7):654–7.

**Additional references****AJCC 2010**

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. *AJCC Cancer Staging Manual*. 7th Edition. New York: Springer, 2010.

**ASA 2014**

American Society of Anesthesiologists. ASA physical status classification System. [www.asahq.org/Home/For-Members/Clinical-Information/ASA-Physical-Status-Classification-System](http://www.asahq.org/Home/For-Members/Clinical-Information/ASA-Physical-Status-Classification-System) (accessed 16 November 2014).

**Bennett 2009**

Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. *Cochrane Database of Systematic Reviews* 2009, Issue 4. [DOI: 10.1002/14651858.CD004276.pub3]

**Bijen 2009**

Bijen CB, Vermeulen KM, Mourits MJ, de Bock GH. Costs and effects of abdominal versus laparoscopic hysterectomy: systematic review of controlled trials. *PLoS One* 2009;**4**(10):e7340.

**Cancer Research UK 2014**

Cancer Research UK. Stomach cancer incidence statistics. [www.cancerresearchuk.org/cancer-info/cancerstats/types/stomach/incidence/#trends](http://www.cancerresearchuk.org/cancer-info/cancerstats/types/stomach/incidence/#trends) (accessed 16 November 2014).

**Clavien 2009**

Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification

- of surgical complications: five-year experience. *Annals of Surgery* 2009;**250**(2):187–96.
- CONSORT 2010**  
Schulz KF, Altman DG, Moher D. Consort 2010 statement: Updated guidelines for reporting parallel group randomized trials. *Annals of Internal Medicine* 2010;**152**(11):726–32.
- Diaz-Nieto 2013**  
Diaz-Nieto R, Orti-Rodriguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. *Cochrane Database of Systematic Reviews* 2013, Issue 9. [DOI: 10.1002/14651858.CD008415.pub2]
- Dindo 2004**  
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Annals of Surgery* 2004;**240**(2):205–13.
- Egger 1997**  
Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical Research Ed.)* 1997;**315**(7109):629–34.
- GRADEproGDT 2015 [Computer program]**  
McMaster University (developed by Evidence Prime, Inc.). GRADEproGDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. Hamilton: McMaster University (developed by Evidence Prime, Inc.), 2015.
- Higgins 2011**  
Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.0.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
- Hopkins 1999**  
Hopkins MP, Dulai RM, Occhino A, Holda S. The effects of carbon dioxide pneumoperitoneum on seeding of tumor in port sites in a rat model. *American Journal of Obstetrics and Gynecology* 1999;**181**(6):1329–34.
- IARC 2014**  
International Agency for Research on Cancer. GLOBOCAN 2012. globocan.iarc.fr/Default.aspx (accessed 16 November 2014).
- ICH-GCP 1996**  
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. *Code of Federal Regulation & ICH Guidelines*. Media: Parexel Barnett, 1996.
- Inaba 2004**  
Inaba T, Okinaga K, Fukushima R, Iinuma H, Ogihara T, Ogawa F, et al. Prospective randomized study of two laparotomy incisions for gastrectomy: midline incision versus transverse incision. *Gastric Cancer* 2004;**7**(3):167–71.
- Inoue 1991**  
Inoue K, Tobe T, Kan N, Nio Y, Sakai M, Takeuchi E, et al. Problems in the definition and treatment of early gastric cancer. *British Journal of Surgery* 1991;**78**(7):818–21.
- Japanese Gastric Cancer Association 2011**  
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines: 3rd English Edition. *Gastric Cancer* 2011;**14**(2):113–23.
- Jemal 2010**  
Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiology, Biomarkers and Prevention* 2010;**19**(8):1893–907.
- Jiang 2013**  
Jiang L, Yang KH, Guan QL, Cao N, Chen Y, Zhao P, et al. Laparoscopy-assisted gastrectomy versus open gastrectomy for resectable gastric cancer: An update meta-analysis based on randomized controlled trials. *Surgical Endoscopy* 2013;**27**(7):2466–80.
- Kais 2014**  
Kais H, Hershkovitz Y, Sandbank J, Halevy A. Port site metastases in squamous cell carcinoma of the gallbladder. *Israel Medical Association Journal* 2014;**16**(3):177–9.
- Keus 2006**  
Keus F, de Jong JA, Gooszen HG, van Laarhoven CJ. Laparoscopic versus open cholecystectomy for patients with symptomatic cholelithiasis. *Cochrane Database of Systematic Reviews* 2006, Issue 4. [DOI: 10.1002/14651858.CD006231]
- Kim 1995**  
Kim JB, Hur YS, Yang HK. Lymph node metastasis as a significant prognostic factor in early gastric cancer: analysis of 1,136 early gastric cancers. *Annals of Surgical Oncology* 1995;**2**(4):308–13.
- Lee 2013**  
Lee HJ, Yang HK. Laparoscopic gastrectomy for gastric cancer. *Digestive Surgery* 2013;**30**(2):132–41.
- Liang 2011**  
Liang Y, Li G, Chen P, Yu J, Zhang C. Laparoscopic versus open gastrectomy for early distal gastric cancer: a meta-analysis. *ANZ Journal of Surgery* 2011;**81**(10):673–80.
- Memon 2011**  
Memon MA, Subramanya MS, Khan S, Hossain MB, Osland E, Memon B. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. *Annals of Surgery* 2011;**253**(5):900–11.
- Moher 2009**  
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. *BMJ* 2009;**339**:2535.
- Palomba 2014**  
Palomba S, Mandato VD, La Sala GB. Isolated port-site metastasis after robotic hysterectomy for stage IA endometrial adenocarcinoma. *Obstetrics and Gynecology* 2014;**123**(3):664.
- Parmar 1998**  
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature

- for survival endpoints. *Statistics in Medicine* 1998;**17**(24): 2815–34.
- RevMan 2014 [Computer program]**  
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
- Reza 2006**  
Reza MM, Blasco JA, Andradas E, Cantero R, Mayol J. Systematic review of laparoscopic versus open surgery for colorectal cancer. *British Journal of Surgery* 2006;**93**(8): 921–8.
- Song 2014**  
Song J, Kim E, Mobley J, Vemana G, Tanagho Y, Vetter J, et al. Port site metastasis after surgery for renal cell carcinoma: harbinger of future metastasis. *Journal of Urology* 2014;**192**(2):364–8.
- SPIRIT 2013**  
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. Spirit 2013 statement: Defining standard protocol items for clinical trials. *Annals of Internal Medicine* 2013;**158**(3):200–7.
- Stuart 1997**  
Stuart RC. 4 - Radical gastrectomy - how do I do it?. *European Journal of Cancer* 1997;**33**(Suppl 8):S5.
- Sun 2012**  
Sun J, Li J, Wang J, Pan T, Zhou J, Fu X, et al. Meta-analysis of randomized controlled trials on laparoscopic gastrectomy vs. open gastrectomy for distal gastric cancer. *Hepato-gastroenterology* 2012;**59**(118):1699–705.
- Talseth 2014**  
Talseth A, Lydersen S, Skjedlestad F, Hveem K, Edna TH. Trends in cholecystectomy rates in a defined population during and after the period of transition from open to laparoscopic surgery. *Scandinavian Journal of Gastroenterology* 2014;**49**(1):92–8.
- Waddell 2013**  
Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 2013;**24**(Suppl 6):vi57–63.
- Walsh 2009**  
Walsh CA, Walsh SR, Tang TY, Slack M. Total abdominal hysterectomy versus total laparoscopic hysterectomy for benign disease: a meta-analysis. *European Journal of Obstetrics, Gynecology, and Reproductive Biology* 2009;**144**(1):3–7.
- Washington 2010**  
Washington K. 7th edition of the AJCC cancer staging manual: stomach. *Annals of Surgical Oncology* 2010;**17**(12): 3077–9.
- Xiong 2013**  
Xiong JJ, Altaf K, Javed MA, Nunes QM, Huang W, Mai G, et al. Roux-en-Y versus Billroth I reconstruction after distal gastrectomy for gastric cancer: a meta-analysis. *World Journal of Gastroenterology* 2013;**19**(7):1124–34.
- Zhang 2015**  
Zhang YX, Wu YJ, Lu GW, Xia MM. Systematic review and meta-analysis of totally laparoscopic versus laparoscopic assisted distal gastrectomy for gastric cancer. *World Journal of Surgical Oncology* 2015;**13**:116.
- References to other published versions of this review**
- Gurusamy 2014**  
Gurusamy KS. Laparoscopic versus open gastrectomy for gastric cancer. *Cochrane Database of Systematic Reviews* 2014, Issue 11. [DOI: 10.1002/14651858.CD011389]  
\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### Aoyama 2014

Methods	Randomised controlled trial	
Participants	Country: Japan Number randomised: 26 Post-randomisation drop-outs: not stated Number analysed: 26 Average age: 65 years Females: 12 (46.2%) Method of Anastomosis: Billroth-I; stapler Type of gastrectomy: Subtotal gastrectomy Cancer stage: Early or advanced stage (T <sub>1-2</sub> N <sub>0-1</sub> ) Totally laparoscopic or LAG: LAG <b>Inclusion criteria</b> Patients undergoing distal gastrectomy for stage I gastric cancer	
Interventions	Participants were randomly assigned to two groups Group 1: laparoscopic gastrectomy (n = 13) Further details: 5 or 6 ports; incision ≤ 6 cm Group 2: open gastrectomy (n = 13) Further details: Upper midline incision (xiphoid to umbilicus) Nodes dissected and drain use: D1 or more nodal dissection; no routine drain	
Outcomes	The outcomes reported were short-term mortality, complications, and lymph nodes harvested	
Notes	Conversion to open gastrectomy: 0/13 (0%) Follow-up period: 30 days	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "Patients are randomized to either the ODG arm or the LADG arm by minimization method balancing the arms with institution and clinical stage (IA/IB)" Comment: This information was not available
Allocation concealment (selection bias)	Low risk	Quote: "After the confirmation of the eligibility criteria, registration is made by telephone, fax or web-based system to the JCOG Data Center. Patients are randomized to either the ODG arm or the LADG arm by minimization method balancing the arms with institution and clinical stage (IA/IB)" Comment: This information was not available

**Aoyama 2014** (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: This information was not available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: This information was not available
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: This information was not available
Selective reporting (reporting bias)	Low risk	Comment: Postoperative mortality and morbidity were reported
Other bias	Low risk	Comment: No other source of bias was identified

**Cai 2011**

Methods	Randomised controlled trial
Participants	<p>Country: China            Number randomised: 123            Post-randomisation drop-outs: 27 (22%)            Number analysed: 96            Average age: 60 years            Females: 20 (20.8%)            Method of Anastomosis: Billroth-I, Billroth-II, oesophagogastrostomy and oesophageal jejunostomy; hand-sewn or stapler anastomosis not stated            Type of gastrectomy: Proximal, distal, or total gastrectomy            Cancer stage: Advanced stage (T<sub>2-3</sub>N<sub>not stated</sub>)            Totally laparoscopic or LAG: LAG</p> <p><b>Inclusion criteria</b>            Patients requiring gastrectomy for gastric cancer</p> <p><b>Exclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Patients needed thoraco-abdominal surgery</li> <li>2. Patients with other malignant tumours</li> <li>3. Patients with upper abdominal large operation history who cannot be fitted for LAG</li> <li>4. Patients with gastric stump cancer and recurrent cancer</li> <li>5. Patients with a surgical risk greater than ASA grade III</li> <li>6. Patients with operative cardiovascular risk greater than New York Heart Association grade II</li> <li>7. Severe liver disease (Child B or C) and renal dysfunction</li> </ol>
Interventions	<p>Participants were randomly assigned to two groups            Group 1: laparoscopic gastrectomy (n = 49)            Further details: 5 ports; upper midline incision about 6 cm            Group 2: open gastrectomy (n = 47)            Further details: Upper midline incision (20 cm)</p>



**Cai 2011** (Continued)

	Nodes dissected and drain use: D2 nodal dissection; drain use not stated
Outcomes	The outcomes reported were short-term mortality, complications, lymph nodes harvested, length of hospital stay, and long-term mortality
Notes	Conversion to open gastrectomy: 2/61 (3.3%) Follow-up period: 22 months Reasons for post-randomisation drop-outs: not clearly reported. The authors state that they performed a subgroup analysis of patients with advanced stage cancer only

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: This information was not available
Allocation concealment (selection bias)	Unclear risk	Comment: This information was not available
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: This information was not available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: This information was not available
Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias)	Low risk	Comment: Postoperative mortality and morbidity were reported
Other bias	Low risk	Comment: No other source of bias was identified

**Chen Hu 2012**

Methods	Randomised controlled trial
Participants	Country: China Number randomised: 88 Post-randomisation drop-outs: 5 (5.7%) Number analysed: 83 Average age: 63 years Females: 41 (49.4%) Method of Anastomosis: Billroth-I or Billroth-II; hand-sewn or stapler anastomosis not stated Type of gastrectomy: Subtotal gastrectomy Cancer stage: Early or advanced stage (T <sub>1-4</sub> N <sub>notstated</sub> )

	<p>Totally laparoscopic or LAG: LAG</p> <p><b>Inclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Age 25-75 years old</li> <li>2. Male or female</li> <li>3. Diagnosis confirmed by endoscopic biopsy</li> <li>4. No lymph node or distant metastasis diagnosed by preoperative abdominal computed tomography</li> <li>5. No history of autoimmune or severe cardiopulmonary diseases</li> <li>6. No preoperative radiotherapy or chemotherapy</li> <li>7. No digestive obstruction, perioperative blood or albumin infusion, combined intraoperative evisceration</li> <li>8. Acceptance by the patients and their families</li> </ol>	
Interventions	<p>Participants were randomly assigned to two groups</p> <p>Group 1: laparoscopic gastrectomy (n = 41)</p> <p>Further details: number of ports not stated; upper midline incision (5 to 8 cm)</p> <p>Group 2: open gastrectomy (n = 44)</p> <p>Further details: Upper midline incision (xiphoid to umbilicus or 2 cm below umbilicus)</p> <p>Nodes dissected and drain use: Nodal dissection not stated; routine drains were used in the part of group who underwent fast-track surgery</p>	
Outcomes	<p>The outcomes reported were short-term mortality, complications, lymph nodes harvested, and hospital stay</p>	
Notes	<p>Conversion to open gastrectomy: not reported</p> <p>Follow-up period: 30 days</p> <p>Reasons for post-randomisation drop-outs: withdrew consent (3); lost to follow-up 2</p>	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: This information was not available
Allocation concealment (selection bias)	Unclear risk	Comment: This information was not available
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Blinding of the surgeons and nurses was not feasible. Therefore, two specially trained doctors blinded to patients' allocated treatment group were in charge for assessing postoperative outcomes and follow-up"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "Blinding of the surgeons and nurses was not feasible. Therefore, two specially trained doctors blinded to patients' allocated treatment group were in charge for assessing postoperative outcomes and follow-up" Comment: It was not clear whether outcomes such as decision to discharge were made by the blinded outcome assessor

Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias)	Low risk	Comment: Postoperative mortality and morbidity were reported
Other bias	Low risk	Comment: No other source of bias was identified

**Deng 2009**

Methods	Randomised controlled trial	
Participants	<p>Country: China                      Number randomised: 53                      Post-randomisation drop-outs: not stated                      Number analysed: 53                      Average age: 51 years                      Females: 27 (50.9%)                      Method of Anastomosis: Billroth-I; hand-sewn or stapler anastomosis not stated                      Type of gastrectomy: Subtotal gastrectomy                      Cancer stage: not stated (<math>T_{not\ stated}N_{not\ stated}</math>)                      Totally laparoscopic or LAG: Possibly totally laparoscopic</p> <p><b>Inclusion criteria</b>                      Patients undergoing distal gastrectomy for gastric cancer</p> <p><b>Exclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Preoperative chemotherapy</li> <li>2. Severe metabolic disorders</li> <li>3. Endocrine or immune system diseases</li> </ol>	
Interventions	<p>Participants were randomly assigned to two groups                      Group 1: laparoscopic gastrectomy (n = 26)                      Further details: 5 ports                      Group 2: open gastrectomy (n = 27)                      Further details: Upper midline incision                      Nodes dissected and drain use: D2 nodal dissection; drain use not stated</p>	
Outcomes	None of the outcomes of interest were reported	
Notes	<p>Conversion to open gastrectomy: not reported                      Follow-up period: until discharge</p>	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: This information was not available

Allocation concealment (selection bias)	Unclear risk	Comment: This information was not available
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: This information was not available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: This information was not available
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: This information was not available
Selective reporting (reporting bias)	High risk	Comment: Postoperative mortality and morbidity were not reported
Other bias	Low risk	Comment: No other source of bias was identified

**Hayashi 2005**

Methods	Randomised controlled trial
Participants	<p>Country: Japan            Number randomised: 28            Post-randomisation drop-outs: 0 (0%)            Number analysed: 28            Average age: 59 years            Females: 6 (21.4%)            Method of Anastomosis: Billroth-I; stapler            Type of gastrectomy: Subtotal gastrectomy            Cancer stage: Early stage (T<sub>1</sub>N<sub>notstated</sub>)            Totally laparoscopic or LAG: LAG</p> <p><b>Inclusion criteria</b>            Patients undergoing distal gastrectomy for early gastric cancer</p> <p><b>Exclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Cancer suitable for EMR</li> <li>2. Cancer located in the upper half of the stomach</li> <li>3. Age exceeding 80 years</li> <li>4. Operative cardiovascular risk greater than New York Heart Association II</li> <li>5. Severe liver disease (Child B or C) and renal dysfunction</li> <li>6. No consent to participate in the study</li> </ol>
Interventions	<p>Participants were randomly assigned to two groups            Group 1: laparoscopic gastrectomy (n = 14)            Further details: 4 ports; upper transverse incision about 6 cm            Group 2: open gastrectomy (n = 14)            Further details: Upper midline incision            Nodes dissected and drain use: D1 nodal dissection; drain use not stated</p>

**Hayashi 2005** (Continued)

Outcomes	The outcomes reported were short-term mortality, complications, lymph nodes harvested, length of hospital stay, and long-term mortality	
Notes	Conversion to open gastrectomy: 0/14 (0%) Follow-up period: 42 months	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: This information was not available
Allocation concealment (selection bias)	Low risk	Quote: "Randomization of the patients into two groups (LADG or ODG) was performed by the blind envelope method on the day before surgery, and the patients were informed of the results the same day"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Randomization of the patients into two groups (LADG or ODG) was performed by the blind envelope method on the day before surgery, and the patients were informed of the results the same day"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: This information was not available
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: There were no post-randomisation drop-outs
Selective reporting (reporting bias)	Low risk	Comment: Postoperative mortality and morbidity were reported
Other bias	Low risk	Comment: No other source of bias was identified

**Hu 2015**

Methods	Randomised controlled trial
Participants	Country: China Number randomised: 607 Post-randomisation drop-outs: 0 (0%) Number analysed: 607 Average age: not stated Females: not stated Method of Anastomosis: no information on type of anastomosis; hand-sewn or stapler anastomosis not stated Type of gastrectomy: Subtotal gastrectomy

	<p>Cancer stage: Advanced stage (T<sub>2-4</sub>N<sub>0-3</sub>)  Totally laparoscopic or LAG: Possibly totally laparoscopic</p> <p><b>Inclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Age from over 18 to under 75 years</li> <li>2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy</li> <li>3. cT2-4a, N0-3, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual Seventh Edition</li> <li>4. Expected curative resection through distal subtotal gastrectomy with D2 lymphadenectomy</li> <li>5. Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale</li> <li>6. ASA score class I, II, or III</li> <li>7. Written informed consent</li> </ol> <p><b>Exclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Women during pregnancy or breast-feeding</li> <li>2. Severe mental disorder</li> <li>3. History of previous upper abdominal surgery (except laparoscopic cholecystectomy)</li> <li>4. History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection</li> <li>5. Enlarged or bulky regional lymph node diameter over 3 cm by preoperative imaging</li> <li>6. History of other malignant disease within past five years</li> <li>7. History of previous neoadjuvant chemotherapy or radiotherapy</li> <li>8. History of unstable angina or myocardial infarction within past six months</li> <li>9. History of cerebrovascular accident within past six months</li> <li>10. History of continuous systematic administration of corticosteroids within one month</li> <li>11. Requirement of simultaneous surgery for other disease</li> <li>12. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer</li> <li>13. FEV1 &lt; 50% of predicted values</li> </ol>
Interventions	<p>Participants were randomly assigned to two groups  Group 1: laparoscopic gastrectomy (n = 308)  Further details: number of ports not stated  Group 2: open gastrectomy (n = 299)  Further details: Incision not stated  Nodes dissected and drain use: D2 nodal dissection; drain use not stated</p>
Outcomes	<p>The outcomes reported were short-term mortality and complications</p>
Notes	<p>Conversion to open gastrectomy: 14/308 (4.5%)  Follow-up period: not reported</p>
<b>Risk of bias</b>	

Hu 2015 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: This information was not available
Allocation concealment (selection bias)	Unclear risk	Comment: This information was not available
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Masking: Open Label"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "Masking: Open Label"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: There were no post-randomisation drop-outs
Selective reporting (reporting bias)	High risk	Comment: The severity of postoperative complications was not reported
Other bias	Low risk	Comment: No other source of bias was identified

Huscher 2005

Methods	Randomised controlled trial
Participants	<p>Country: Italy            Number randomised: 70            Post-randomisation drop-outs: 11 (15.7%)            Number analysed: 59            Average age: 64 years            Females: 20 (33.9%)            Method of Anastomosis: Billroth-I or Billroth-II; some anastomoses by stapler and others by hand-sewn anastomoses            Type of gastrectomy: Subtotal gastrectomy            Cancer stage: Early or advanced stage (T<sub>1-4</sub>N<sub>0-2</sub>)            Totally laparoscopic or LAG: Possibly totally laparoscopic</p> <p><b>Inclusion criteria</b>            Patients undergoing subtotal gastrectomy for distal gastric cancer</p>
Interventions	<p>Participants were randomly assigned to two groups            Group 1: laparoscopic gastrectomy (n = 30)            Further details: 4 ports            Group 2: open gastrectomy (n = 29)            Further details: Incision not stated            Nodes dissected and drain use: D1 or D2 nodal dissection; drain use not stated</p>

**Huscher 2005** (Continued)

Outcomes	The outcomes reported were short-term mortality, complications, lymph nodes harvested, length of hospital stay, long-term mortality, and long-term recurrence	
Notes	Conversion to open gastrectomy: not reported Follow-up period: 52 months Reasons for post-randomisation drop-outs: extension beyond distal cancer; metastases	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: This information was not available
Allocation concealment (selection bias)	Unclear risk	Comment: This information was not available
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: This information was not available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: This information was not available
Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias)	Low risk	Comment: Postoperative mortality and morbidity were reported
Other bias	Low risk	Comment: No other source of bias was identified

**Kim 2013**

Methods	Randomised controlled trial
Participants	Country: South Korea Number randomised: 204 Post-randomisation drop-outs: 9 (4.4%) Number analysed: 195 Average age: not stated Females: not stated Method of Anastomosis: no information on type of anastomosis; hand-sewn or stapler anastomosis not stated Type of gastrectomy: Subtotal gastrectomy Cancer stage: Advanced stage (T <sub>2-4</sub> N <sub>0-3</sub> ) Totally laparoscopic or LAG: LAG <b>Inclusion criteria</b>



	<ol style="list-style-type: none"> <li>1. Patients with clinically advanced stage non metastatic, histologically proven gastric cancer (cT2-4 N0-3 M0) according to the sixth union for international cancer control edition)</li> <li>2. Aged between 20 to 80 years</li> </ol> <p><b>Exclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Participation in another trial interfering with the outcome of this study</li> <li>2. Language problems</li> <li>3. Lack of compliance</li> <li>4. Mental inability</li> <li>5. Synchronous or previous malignant disease (except curatively treated in situ cervical cancer or curatively resected non-melanoma skin cancer)</li> <li>6. Systemic administration of corticosteroids</li> <li>7. Unstable angina or myocardial infarction within 6 months of the trial</li> <li>8. Severe respiratory disease</li> <li>9. ASA score &gt; 3</li> <li>10. Previous major abdominal surgery</li> <li>11. Previous chemo- or radiotherapy</li> <li>12. Inadequate liver, kidney- and bone-marrow functions</li> <li>13. Eastern Cooperative Oncology Group status &gt; 1</li> </ol>	
Interventions	<p>Participants were randomly assigned to two groups</p> <p>Group 1: laparoscopic gastrectomy (n = 100)</p> <p>Further details: number of ports and incision size not stated</p> <p>Group 2: open gastrectomy (n = 95)</p> <p>Further details: Incision not stated</p> <p>Nodes dissected and drain use: D2 nodal dissection; drain use not stated</p>	
Outcomes	The outcomes reported were complications	
Notes	<p>Conversion to open gastrectomy: not reported</p> <p>Follow-up period: 30 days</p> <p>Reasons for post-randomisation drop-outs: protocol violation and withdrawal of patient permission</p>	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "Randomization is performed as block randomization in fixed block sizes in a 1:1 allocation ratio using a centralized web-based randomization system (eVelos [http://eresearch.ncc.re.kr/eres/jsp/ereslogin.jsp])"
Allocation concealment (selection bias)	Low risk	Quote: "Randomization is performed as block randomization in fixed block sizes in a 1:1 allocation ratio using a centralized web-based randomization system (eVelos [http://eresearch.ncc.re.kr/eres/jsp/ereslogin.jsp])"

**Kim 2013** (Continued)

Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Blinding procedures are not possible in this trial due to the nature of the intervention"
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "However blinded assessment of the primary & secondary outcomes were provided by blinded observers" (author replies) Comment: It is unclear how the decision on hospital discharge and serious adverse events were assessed (for example, by a second surgical team)
Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias)	High risk	Comment: Mortality and the severity of postoperative complications were not reported
Other bias	Low risk	Comment: No other source of bias was identified

**Kim 2015**

Methods	Randomised controlled trial
Participants	<p>Country: South Korea            Number randomised: 1416            Post-randomisation drop-outs: 160 (11.3%)            Number analysed: 1256            Average age: not stated            Females: not stated            Method of Anastomosis: Billroth-I, Billroth-II, or Roux-en-Y anastomosis; hand-sewn or stapler anastomosis not stated            Type of gastrectomy: Subtotal gastrectomy            Cancer stage: Early or advanced stage (T<sub>1-2</sub>N<sub>0-1</sub>)            Totally laparoscopic or LAG: LAG</p> <p><b>Inclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Pathologically proven gastric adenocarcinoma</li> <li>2. Age of 20 to 80 years</li> <li>3. A preoperative stage of cT1N0M0, cT1N1m0, cT2aN0M0 according to American Joint Committee on Cancer/Union for International Cancer Control 6th edition</li> <li>4. No history of other cancers</li> <li>5. No history of chemotherapy or radiotherapy</li> </ol> <p><b>Exclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. ASA class &gt; 3</li> <li>2. Need for combined resection</li> <li>3. Total gastrectomy</li> </ol>

Interventions	<p>Participants were randomly assigned to two groups            Group 1: laparoscopic gastrectomy (n = 644)            Further details: number of ports and incision size not stated            Group 2: open gastrectomy (n = 612)            Further details: Incision not stated            Nodes dissected and drain use: D1 or more nodal dissection; drain use not stated</p>	
Outcomes	<p>The outcomes reported were short-term mortality and complications</p>	
Notes	<p>Conversion to open gastrectomy: not reported            Follow-up period: 30 days            Reasons for post-randomisation drop-outs: Patients who switched to the other group's approach and underwent other than distal gastrectomy or combined resection except cholecystectomy</p>	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "After confirming the patients met the inclusion/exclusion criteria by telephoning the data center, the patients were registered into the trial and then randomized to one of two groups (LADG or ODG) on the basis of a computer-generated randomization list"
Allocation concealment (selection bias)	Low risk	Quote: "Randomization was coordinated centrally by the independent data center and aimed to balance the arms according to each institution"
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: This information was not available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: This information was not available
Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias)	High risk	Comment: The severity of postoperative complications was not reported
Other bias	Low risk	Comment: No other source of bias was identified

**Kitano 2002**

Methods	Randomised controlled trial
Participants	<p>Country: Japan            Number randomised: 28            Post-randomisation drop-outs: not stated            Number analysed: 28            Average age: 62 years            Females: 11 (39.3%)            Method of Anastomosis: Billroth-I; hand-sewn or stapler anastomosis not stated            Type of gastrectomy: Subtotal gastrectomy            Cancer stage: Early stage (T<sub>1</sub>N<sub>0</sub>)            Totally laparoscopic or LAG: LAG</p> <p><b>Inclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Patients undergoing distal gastrectomy for early gastric cancer</li> <li>2. At risk of perigastric lymph node metastasis precluding endoscopic mucosal resection</li> </ol> <p><b>Exclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Age over 80 years</li> <li>2. Operative cardiovascular risk greater than that of New York Heart Association class II</li> <li>3. Operative pulmonary risk greater than that of Hugh-Jones class II</li> <li>4. Severe liver disease (Child class B or C) or renal dysfunction</li> </ol>
Interventions	<p>Participants were randomly assigned to two groups            Group 1: laparoscopic gastrectomy (n = 14)            Further details: number of ports not stated; upper midline incision (5 cm)            Group 2: open gastrectomy (n = 14)            Further details: Upper midline incision            Nodes dissected and drain use: Nodal dissection not stated; drain use not stated</p>
Outcomes	The outcomes reported were short-term mortality, complications, and long-term recurrence
Notes	<p>Conversion to open gastrectomy: 0/14 (0%)            Follow-up period: 26 months</p>

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: This information was not available
Allocation concealment (selection bias)	Low risk	Quote: "After providing written informed consent, the patients were randomly assigned to either LADG group (n = 10) and an ODG group (n = 10) with Billroth-I reconstruction on the day before operation by use of numbered, sealed envelopes that were stratified by the surgeon"

**Kitano 2002** (Continued)

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: This information was not available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: This information was not available
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: This information was not available
Selective reporting (reporting bias)	High risk	Comment: The severity of postoperative complications was not reported
Other bias	Low risk	Comment: No other source of bias was identified

**Lee 2005**

Methods	Randomised controlled trial
Participants	<p>Country: South Korea            Number randomised: 47            Post-randomisation drop-outs: not stated            Number analysed: 47            Average age: 58 years            Females: 21 (44.7%)            Method of Anastomosis: Billroth-I; stapler            Type of gastrectomy: Subtotal gastrectomy            Cancer stage: Early stage (T<sub>1</sub>N<sub>0</sub>)            Totally laparoscopic or LAG: LAG</p> <p><b>Inclusion criteria</b>            Patients with early gastric cancer undergoing distal gastrectomy</p> <p><b>Exclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Patients who had mucosal lesions that were suitable for an endoscopic mucosal resection (lesion size &lt; 20 mm in the elevated type and &lt; 10 mm in the depressed type)</li> <li>2. A surgical risk greater than ASA III</li> <li>3. Lesions proximal to the midbody</li> <li>4. A previous history of upper abdominal surgery</li> <li>5. Need for combined surgery to treat another disease</li> </ol>
Interventions	<p>Participants were randomly assigned to two groups            Group 1: laparoscopic gastrectomy (n = 24)            Further details: 4 ports; upper midline incision about 7 cm            Group 2: open gastrectomy (n = 23)            Further details: Upper midline incision (about 20 cm)            Nodes dissected and drain use: Selected nodes in laparoscopic group and D2 nodal dissection in open group; drain used routinely in laparoscopic group; information on drain use in open group was not available</p>

Lee 2005 (Continued)

Outcomes	The outcomes reported were short-term mortality, complications, lymph nodes harvested, length of hospital stay, and long-term recurrence	
Notes	Conversion to open gastrectomy: 0/24 (0%) Follow-up period: 14 months	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "Using a random number table, 23 patients were assigned to the open surgery group (group O) and 24 patients were assigned to the LADG group (group L)"
Allocation concealment (selection bias)	Unclear risk	Comment: This information was not available
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: This information was not available
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: This information was not available
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: This information was not available.
Selective reporting (reporting bias)	High risk	Comment: The severity of postoperative complications was not reported
Other bias	High risk	Comment: A more extensive procedure was performed in open gastrectomy group compared to laparoscopic group. This could potentially favour laparoscopic group in terms of decreased complications but favour open group in terms of decreased long-term recurrence and mortality

Sakuramoto 2013

Methods	Randomised controlled trial
Participants	Country: Japan Number randomised: 64 Post-randomisation drop-outs: 1 (1.6%) Number analysed: 63 Average age: 60 years Females: 21 (33.3%) Method of Anastomosis: Billroth-I; stapler Type of gastrectomy: Subtotal gastrectomy

	<p>Cancer stage: Early stage (T<sub>1</sub>N<sub>0</sub>)          Totally laparoscopic or LAG: LAG</p> <p><b>Inclusion criteria</b>          Over 20 and under 75 years of age with gastric cancer in the middle or lower part of the stomach for which distal gastrectomy was indicated</p> <p><b>Exclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Past history of gastric cancer</li> <li>2. Previous open surgery of the upper abdomen</li> <li>3. Past history of other types of cancers and cancer treatment</li> <li>4. Serious heart, lung, kidney, blood and/or metabolic disease</li> <li>5. New York Heart Association class III or IV classification of cardiac patients</li> <li>6. Class III, IV, or V of the Hugh-Jones dyspnoea criteria</li> </ol>	
Interventions	<p>Participants were randomly assigned to two groups</p> <p>Group 1: laparoscopic gastrectomy (n = 31)          Further details: 4 ports; upper abdominal incision about 5 cm</p> <p>Group 2: open gastrectomy (n = 32)          Further details: Upper midline incision (xiphoid to umbilicus)</p> <p>Nodes dissected and drain use: Selected group of nodes in the two groups; drains used routinely in both groups</p>	
Outcomes	<p>The outcomes reported were short-term mortality, complications, and length of hospital stay</p>	
Notes	<p>Conversion to open gastrectomy: not reported          Follow-up period: until discharge          Reasons for post-randomisation drop-outs: concurrent illness</p>	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "The computer-generated, nonstratified, blocked randomization scheme was managed centrally and concealed at the moment of inclusion"
Allocation concealment (selection bias)	Low risk	Quote: "The computer-generated, nonstratified, blocked randomization scheme was managed centrally and concealed at the moment of inclusion"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "Due to the pragmatic nature of the trial, surgeons, care providers, and patients could not be blinded to the type of treatment that was performed"
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "Due to the pragmatic nature of the trial, surgeons, care providers, and patients could not be blinded to the type of treatment that was performed"

Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: There were post-randomisation drop-outs
Selective reporting (reporting bias)	High risk	Comment: Postoperative mortality and morbidity were reported
Other bias	Low risk	Comment: No other source of bias was identified

**Takiguchi 2013**

Methods	Randomised controlled trial
Participants	<p>Country: Japan                      Number randomised: 40                      Post-randomisation drop-outs: not stated                      Number analysed: 40                      Average age: 62 years                      Females: 15 (37.5%)                      Method of Anastomosis: Billroth-I; stapler                      Type of gastrectomy: Subtotal gastrectomy                      Cancer stage: Early stage (T<sub>1</sub>N<sub>0-1</sub>)                      Totally laparoscopic or LAG: LAG</p> <p><b>Inclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Age between 20 and 80 years</li> <li>2. Performance status of ECOG (Eastern Cooperative Oncology Group) 0-1</li> <li>3. Signed informed consent</li> <li>4. Location of the primary tumour in the antrum, angle, and lower body</li> <li>5. Histologically confirmed adenocarcinoma of the stomach with preoperative staging of stage Ia or Ib (no evidence of distant metastasis or invasion of adjacent organs or serosal infiltration by abdominal computed tomography [CT] and chest x-ray film and regional lymph node metastasis confined to perigastric nodes [n1] as shown on CT scan)</li> </ol> <p><b>Exclusion criteria</b></p> <ol style="list-style-type: none"> <li>1. Metastatic disease</li> <li>2. Previous history of malignancy in any organ</li> <li>3. Any comorbidity obviating major surgery</li> <li>4. Contraindication to laparoscopy such as severe cardiac disease, abdominal wall hernias, portal hypertension, pregnancy, previous upper abdominal major surgery excluding appendectomy and laparoscopic cholecystectomy.</li> <li>5. Complicated cases requiring emergency surgery</li> <li>6. An accompanying surgical condition requiring surgery at the same time</li> </ol>
Interventions	<p>Participants were randomly assigned to two groups                      Group 1: laparoscopic gastrectomy (n = 20)                      Further details: 5 ports; midline incision about 4 to 6 cm                      Group 2: open gastrectomy (n = 20)                      Further details: Incision not stated                      Nodes dissected and drain use: Selected group of nodes in the two groups; drains used</p>



**Takiguchi 2013** (Continued)

	in laparoscopic group, no details in open group	
Outcomes	The outcomes reported were short-term mortality, blood transfusion, length of hospital stay, lymph node harvest, and long-term mortality	
Notes	Conversion to open gastrectomy: 0/20 (0%) Follow-up period: 60 months	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Comment: This information was not available
Allocation concealment (selection bias)	Low risk	Quote: "Randomization of the patients into two groups was performed by the blind envelop method on the day before operation, but the patients were not informed of the results at that time"
Blinding of participants and personnel (performance bias) All outcomes	High risk	Comment: This was a single-blinded study in which only patients were blinded
Blinding of outcome assessment (detection bias) All outcomes	High risk	Comment: This was a single-blinded study in which only patients were blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: There were no post-randomisation drop-outs
Selective reporting (reporting bias)	High risk	Comment: The complications in the laparoscopic gastrectomy group and the severity of postoperative complications in the open gastrectomy group were not reported
Other bias	Low risk	Comment: No other source of bias was identified

**ASA:** American Society of Anesthesiologist; **EMR:** Endoscopic mucosal resection; **FEV1:** forced expiratory volume in first second;

**JCOG:** Japan Clinical Oncology Group; **LADG:** laparoscopy-assisted distal gastrectomy; **LAG:** laparoscopy-assisted gastrectomy;

**ODG:** open distal gastrectomy

T: Tumour stage of TNM classification

N: Nodal stage of TNM classification

Example: T<sub>1-2</sub>N<sub>0-1</sub>: indicates T-stage 1 or 2 and N-stage 0 or 1

Early gastric cancer: clinical stage: T<sub>1</sub>N<sub>any</sub>

Advanced gastric cancer: T<sub>>1</sub>N<sub>any</sub>

### Characteristics of excluded studies *[ordered by study ID]*

Study	Reason for exclusion
Han 2014	Not a randomised controlled trial
Kanellos 2009	Editorial
Kawamura 2008	Not a randomised controlled trial
Kim 2008	Quasi-randomised study
Kim 2009	Comment on an excluded study ( <a href="#">Kim 2008</a> )
Lee 2008	Not a randomised controlled trial
Lee 2009	Not a randomised controlled trial
Li 2014	Not a randomised controlled trial
Liakakos 2009	Comment on an excluded study ( <a href="#">Kim 2008</a> )
Lin 2014	Not a randomised controlled trial
Sakuramoto 2009	Not a randomised controlled trial

### Characteristics of ongoing studies *[ordered by study ID]*

#### Haverkamp 2015

Trial name or title	LOGICA
Methods	Randomised controlled trial
Participants	Early or advanced staged gastric adenocarcinoma
Interventions	Laparoscopy-assisted versus open distal or total gastrectomy
Outcomes	Mortality, adverse events, health-related quality of life, length of hospital stay, clear resection margins, number of lymph nodes dissected, and long-term mortality
Starting date	December 2014
Contact information	R.vanHillegersberg@umcutrecht.nl
Notes	

**Straatman 2015**

Trial name or title	STOMACH
Methods	Randomised controlled trial
Participants	People with early or advanced gastric cancer receiving neoadjuvant chemotherapy
Interventions	Laparoscopy-assisted versus open total gastrectomy
Outcomes	Mortality, health-related quality of life, length of hospital stay, number of lymph nodes dissected, and long-term mortality
Starting date	Not stated
Contact information	je.straatman@vumc.nl
Notes	

**Yoshikawa 2012**

Trial name or title	LANDSCOPE
Methods	Randomised controlled trial
Participants	People with advanced gastric cancer receiving neoadjuvant chemotherapy
Interventions	Laparoscopy-assisted versus open distal gastrectomy
Outcomes	Mortality, adverse events, and long-term recurrence
Starting date	December 2014
Contact information	yoshikawat@kcch.jp
Notes	

## DATA AND ANALYSES

### Comparison 1. Laparoscopic versus open gastrectomy

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Short-term mortality	11	2335	Risk Ratio (M-H, Fixed, 95% CI)	1.60 [0.50, 5.10]
2 Long-term mortality (maximal follow-up)	3	195	Hazard Ratio (Fixed, 95% CI)	0.94 [0.70, 1.25]
3 Proportion with a serious adverse event (< 3 months)	8	432	Risk Ratio (M-H, Fixed, 95% CI)	0.60 [0.27, 1.34]
4 Short-term recurrence	3		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
5 Long-term recurrence (maximal follow-up)	4		Hazard Ratio (Fixed, 95% CI)	Totals not selected
6 Proportion with an adverse event (< 3 months)	11	2490	Risk Ratio (M-H, Random, 95% CI)	0.78 [0.60, 1.01]
7 Proportion requiring blood transfusion during or within a week of surgery	2		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
8 Quantity of perioperative blood transfused	2	143	Std. Mean Difference (IV, Fixed, 95% CI)	0.05 [-0.27, 0.38]
9 Length of hospital stay	8	444	Mean Difference (IV, Random, 95% CI)	-1.38 [-2.57, -0.19]
10 Proportion with positive resection margins at histopathological examination	1		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
11 Number of lymph nodes harvested	9	472	Mean Difference (IV, Fixed, 95% CI)	-0.63 [-1.51, 0.25]

### Comparison 2. Laparoscopic versus open gastrectomy (subgroup analysis)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Short-term mortality (stratified by early versus advanced cancer)	7		Risk Ratio (M-H, Fixed, 95% CI)	Totals not selected
1.1 Early gastric cancer	5		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Advanced gastric cancer	2		Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Long-term mortality (maximal follow-up) (stratified by early versus advanced cancer)	2		Hazard Ratio (Fixed, 95% CI)	Totals not selected
2.1 Early gastric cancer	1		Hazard Ratio (Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 Advanced gastric cancer	1		Hazard Ratio (Fixed, 95% CI)	0.0 [0.0, 0.0]


3 Proportion with a serious adverse event (< 3 months) (stratified by early versus advanced cancer)	5	262	Risk Ratio (M-H, Fixed, 95% CI)	0.58 [0.21, 1.60]
3.1 Early gastric cancer	4	166	Risk Ratio (M-H, Fixed, 95% CI)	0.44 [0.14, 1.39]
3.2 Advanced gastric cancer	1	96	Risk Ratio (M-H, Fixed, 95% CI)	2.88 [0.12, 68.98]
4 Short-term mortality (stratified by type of gastrectomy)	10		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
4.1 Subtotal gastrectomy	10	2239	Risk Ratio (M-H, Fixed, 95% CI)	1.60 [0.50, 5.10]
5 Long-term mortality (maximal follow-up) (stratified by type of gastrectomy)	2		Hazard Ratio (Fixed, 95% CI)	Totals not selected
5.1 Subtotal gastrectomy	2		Hazard Ratio (Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Proportion with a serious adverse event (< 3 months) (stratified by type of gastrectomy)	7		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
6.1 Subtotal gastrectomy	7	336	Risk Ratio (M-H, Fixed, 95% CI)	0.52 [0.22, 1.22]

### Analysis 1.1. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 1 Short-term mortality.

Review: Laparoscopic versus open gastrectomy for gastric cancer


Comparison: 1 Laparoscopic versus open gastrectomy

Outcome: 1 Short-term mortality



(Continued ...)

(... Continued)




### Analysis 1.2. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 2 Long-term mortality (maximal follow-up).

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 1 Laparoscopic versus open gastrectomy

Outcome: 2 Long-term mortality (maximal follow-up)




### Analysis 1.3. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 3 Proportion with a serious adverse event (< 3 months).

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 1 Laparoscopic versus open gastrectomy

Outcome: 3 Proportion with a serious adverse event (< 3 months)




### Analysis I.4. Comparison I Laparoscopic versus open gastrectomy, Outcome 4 Short-term recurrence.

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: I Laparoscopic versus open gastrectomy

Outcome: 4 Short-term recurrence



### Analysis I.5. Comparison I Laparoscopic versus open gastrectomy, Outcome 5 Long-term recurrence (maximal follow-up).

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: I Laparoscopic versus open gastrectomy

Outcome: 5 Long-term recurrence (maximal follow-up)






### Analysis 1.6. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 6 Proportion with an adverse event (< 3 months).

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 1 Laparoscopic versus open gastrectomy

Outcome: 6 Proportion with an adverse event (< 3 months)




**Analysis 1.7. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 7 Proportion requiring blood transfusion during or within a week of surgery.**

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 1 Laparoscopic versus open gastrectomy

Outcome: 7 Proportion requiring blood transfusion during or within a week of surgery




**Analysis 1.8. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 8 Quantity of perioperative blood transfused.**

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 1 Laparoscopic versus open gastrectomy

Outcome: 8 Quantity of perioperative blood transfused




### Analysis 1.9. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 9 Length of hospital stay.

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 1 Laparoscopic versus open gastrectomy

Outcome: 9 Length of hospital stay




**Analysis 1.10. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 10 Proportion with positive resection margins at histopathological examination.**

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 1 Laparoscopic versus open gastrectomy

Outcome: 10 Proportion with positive resection margins at histopathological examination




**Analysis 1.11. Comparison 1 Laparoscopic versus open gastrectomy, Outcome 11 Number of lymph nodes harvested.**

Review: Laparoscopic versus open gastrectomy for gastric cancer


Comparison: 1 Laparoscopic versus open gastrectomy

Outcome: 11 Number of lymph nodes harvested



(Continued ...)

(... Continued)




### Analysis 2.1. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 1 Short-term mortality (stratified by early versus advanced cancer).

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)

Outcome: 1 Short-term mortality (stratified by early versus advanced cancer)




**Analysis 2.2. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 2 Long-term mortality (maximal follow-up) (stratified by early versus advanced cancer).**

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)

Outcome: 2 Long-term mortality (maximal follow-up) (stratified by early versus advanced cancer)




### Analysis 2.3. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 3 Proportion with a serious adverse event (< 3 months) (stratified by early versus advanced cancer).

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)

Outcome: 3 Proportion with a serious adverse event (< 3 months) (stratified by early versus advanced cancer)




**Analysis 2.4. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 4 Short-term mortality (stratified by type of gastrectomy).**

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)

Outcome: 4 Short-term mortality (stratified by type of gastrectomy)






**Analysis 2.5. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 5 Long-term mortality (maximal follow-up) (stratified by type of gastrectomy).**

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)

Outcome: 5 Long-term mortality (maximal follow-up) (stratified by type of gastrectomy)




## Analysis 2.6. Comparison 2 Laparoscopic versus open gastrectomy (subgroup analysis), Outcome 6 Proportion with a serious adverse event (< 3 months) (stratified by type of gastrectomy).

Review: Laparoscopic versus open gastrectomy for gastric cancer

Comparison: 2 Laparoscopic versus open gastrectomy (subgroup analysis)

Outcome: 6 Proportion with a serious adverse event (< 3 months) (stratified by type of gastrectomy)



## APPENDICES

### Appendix I. CENTRAL search strategy

#1 (carcin\* or cancer\* or neoplas\* or tumour\* or tumor\* or cyst\* or growth\* or adenocarcin\* or malig\*)

#2 (Intestin\* or Digest\* or Gastr\* or gut or epigastr\* or stomach\* or abdomin\*)

#3 #1 or #2

#4 MeSH descriptor: [Abdominal Neoplasms] explode all trees

#5 MeSH descriptor: [Intestinal Neoplasms] explode all trees

#6 MeSH descriptor: [Stomach Neoplasms] explode all trees

#7 #4 or #5 or #6

#8 #3 or #7

#9 (laparoscopy or laparoscopic)

#10 MeSH descriptor: [Laparoscopy] explode all trees

Laparoscopic versus open gastrectomy for gastric cancer (Review)

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

#11 #9 or #10  
#12 gastrectomy  
#13 MeSH descriptor: [Gastrectomy] explode all trees  
#14 #12 or #13  
#15 #8 and #11 and #14

## Appendix 2. MEDLINE search strategy

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. (carcin\* or cancer\* or neoplas\* or tumour\* or tumor\* or cyst\* or growth\* or adenocarcin\* or malig\*).mp.
13. (Intestin\* or Digest\* or Gastr\* or gut or epigastr\* or stomach\*).mp.
14. 12 and 13
15. exp abdominal neoplasms/ or exp intestinal neoplasms/ or exp stomach neoplasms/
16. 14 or 15
17. (laparoscopy or laparoscopic).mp.
18. exp Laparoscopy/
19. 17 or 18
20. exp Gastrectomy/
21. gastrectomy.mp.
22. 20 or 21
23. 16 and 19 and 22
24. 11 and 23

## Appendix 3. EMBASE search strategy

1. Clinical trial/
2. Randomized controlled trial/
3. Randomization/
4. Single-Blind Method/
5. Double-Blind Method/
6. Cross-Over Studies/
7. Random Allocation/
8. Placebo/
9. Randomi?ed controlled trial\*.tw.
10. Rct.tw.
11. Random allocation.tw.
12. Randomly allocated.tw.
13. Allocated randomly.tw.
14. (allocated adj2 random).tw.
15. Single blind\*.tw.
16. Double blind\*.tw.
17. ((treble or triple) adj blind\*).tw.

18. Placebo\*.tw.
19. Prospective study/
20. or/1-19
21. Case study/
22. Case report.tw.
23. Abstract report/ or letter/
24. or/21-23
25. 20 not 24
26. (carcin\* or cancer\* or neoplas\* or tumour\* or tumor\* or cyst\* or growth\* or adenocarcin\* or malig\*).mp.
27. exp neoplasm/ or exp tumor/
28. 26 or 27
29. (Intestin\* or Digest\* or Gastr\* or gut or epigastr\* or stomach\*).mp.
30. 28 and 29
31. exp stomach tumor/ or exp abdominal tumor/ or exp stomach cancer/ or exp abdominal cancer/ or exp intestine cancer/ or exp stomach carcinoma/ or exp stomach carcinogenesis/ or exp stomach carcinoid/
32. 30 or 31
33. (laparoscopy or laparoscopic).mp.
34. exp laparoscopy/
35. 33 or 34
36. exp gastrectomy Billroth I/ or exp gastrectomy/ or exp partial gastrectomy/ or exp gastrectomy Billroth II/
37. gastrectomy.mp.
38. 36 or 37
39. 32 and 35 and 38
40. 25 and 39

#### **Appendix 4. Science Citation Index search strategy**

- #1 TS=(carcin\* or cancer\* or neoplas\* or tumour\* or tumor\* or cyst\* or growth\* or adenocarcin\* or malig\*)
- #2 TS=(Intestin\* or Digest\* or Gastr\* or gut or epigastr\* or stomach\*)
- #3 TS=(laparoscopy or laparoscopic)
- #4 TS=(gastrectomy)
- #5 TS=(random\* OR rct\* OR crossover OR masked OR blind\* OR placebo\* OR meta-analysis OR systematic review\* OR meta-analys\*)
- #6 #5 AND #4 AND #3 AND #2 AND #1

#### **Appendix 5. ClinicalTrials.gov search strategy**

“Interventional” [STUDY-TYPES] AND gastrectomy [DISEASE] AND (laparoscopy OR laparoscopic) [TREATMENT] AND ( “Phase 2” OR “Phase 3” OR “Phase 4” ) [PHASE]

#### **Appendix 6. WHO ICTRP search strategy**

Gastrectomy AND laparoscop\*

## WHAT'S NEW

Last assessed as up-to-date: 5 September 2015.

Date	Event	Description
31 March 2016	Amended	The results section of the abstract was amended to correct a typographic error calculating 7/1188 as 6% rather than 0.6%

## CONTRIBUTIONS OF AUTHORS

Conceiving the review: KG.

Designing the review: KG, MM.

Co-ordinating the review: KG.

Designing search strategies: KG.

Writing the review: LB, KG.

Providing general advice on the review: MM.

Securing funding for the review: KG.

Performing previous work that was the foundation of the current study: KG.

## DECLARATIONS OF INTEREST

This report is independent research, funded by the National Institute for Health Research (NIHR Cochrane Programme Grants, 13/89/03 - Evidence-based diagnosis and management of upper digestive, hepato-biliary, and pancreatic disorders). The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the National Institute for Health Research, or the Department of Health.

LMJB: none known.

MM: none known.

KSG: none known.

## SOURCES OF SUPPORT

### **Internal sources**

- University College London, UK.

### **External sources**

- National Institute for Health Research, UK.

This report is independent research, funded by the National Institute for Health Research (NIHR Cochrane Programme Grants, 13/89/03 - Evidence-based diagnosis and management of upper digestive, hepato-biliary, and pancreatic disorders). The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the National Institute for Health Research, or the Department of Health.

## **DIFFERENCES BETWEEN PROTOCOL AND REVIEW**

The search strategy was revised after the protocol was published as it was not sufficiently sensitive to identify known trials.